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INTRODUCTION  
 
 
 
A) MICROBIOLOGY  
 
 
Pseudomonas aeruginosa (in latin: aeruginosus meaning “covered in rust”) is a member of the 
Pseudomonadaceae family. This Gram-negative rod is motile, grows aerobically, and produces a 
characteristic sweet grape odor in culture. It is ubiquitous and is therefore found in a wide range of 
places, but with a predilection for moist environments such as water, soil, plants and raw 
vegetables,(e.g. salads). In hospitals, respiratory equipments, physiotherapy pools, disinfectants, sinks, 
flowers and mops can be reservoirs for P. aeruginosa. 
P. aeruginosa is an opportunistic human pathogen, almost exclusively infecting patients with 
an underlying immunosuppression, ranging from neutropenic cancer patients to critically ill 
mechanically ventilated patients. In fact, it is considered to be the prototype of “the hospital bacteria”. 
P. aeruginosa can produce a wide range of infections in humans, the most important being nosocomial 
pneumonia. P. aeruginosa is one of the most common causes of ventilator associated pneumonia 
(VAP) in intubated patients (1,2). It is also responsible for nosocomial urinary tract infections and 
bacteremia. It is less frequently responsible for surgical or burn wounds infections, malignant external 
otitis in diabetics, gastrointestinal infections such as abscesses, cholangitis, peritonitis, pancreatitis, 
osteomyelitis, keratitis (panophtalmitis) and finally endocarditis in iv drug users.  
P. aeruginosa owes its pathogenic potential to several features. This bacteria produces an 
important number of virulence factors, which are either cell-associated, such as the flagellum, the pili, 
the LPS and an extracellular matrix called biofilm, or secreted compounds having a specific enzymatic 
activity. More then half of the clinical isolates produce the fluorescent pigment pyocyanin.   
Implanted in the external membrane are the polar flagella and pili, which are not only 
responsible for motility but also play a role in adhesion to mucosal membranes (3), and the 
lipopolysacharides, which are macromolecular complexes also called endotoxin, responsible for the 
induction of the major inflammatory host response. Under certain conditions, P. aeruginosa produces 
an extracellular matrix, referred to as the biofilm. This matrix is essential for colonisation of inert 
3surfaces and might also play a role in the interaction with epithelial cells. In the specific lung 
environment of cystic fibrosis patients, P. aeruginosa forms so called mucoid colonies that produce a 
very thick and slimy matrix consisting of mannuronic and guluronic acid in a repeating structure that is 
termed alginate. These mucoid strains are known to be more resistant to phagocytosis and less 
susceptible to antibiotic killing (4). 
P. aeruginosa also produces a number of secreted virulence factors. The proteases, mainly 
elastase and alkaline protease, play an important role during tissue invasion, for example, by degrading 
elastin fibers in lung tissue, as well as laminin and elastin fibers in the basal membrane of vascular 
tissue, and destroying connections between cells, such as in the cornea and the human respiratory 
epithelium. The hemolysins, rhamnolipids and phospholipase C, also contribute to tissue destruction, 
owing to their cytotoxic action and their potential for degrading the lung’s surfactant. They work in a 
synergistic manner: rhamnolipids solubilise lipids, thereby facilitating the action of phospholipase C 
which hydrolyses the phospholipids of cytoplasmic membranes. Exotoxine A plays a role in the 
systemic toxicity of P. aeruginosa, by inhibiting protein synthesis in a similar way to the diphteria 
toxin. The expression of several of these exoproducts is regulated and coordinated by sophisticated 
cell-to-cell signaling systems modulated by cell density (the quorum-sensing phenomenon) (3). Their 
phenotypic expression  also varies according to their site of isolation (6). 
On top of these, P. aeruginosa, like other Gram-negative bacteria, produces a special secretion 
system, named type III secretion system, which serves to inject toxins directly into adjacent host cells. 
It consists of three coordinately functioning protein complexes, namely the secretion and translocation 
apparatus and the secreted toxins themselves, which in the case of P. aeruginosa are called ExoS, 
ExoT, ExoU and ExoY. It has been recently determined that the expression of these type III secretory 
proteins in respiratory isolates is associated with the patient’s death and an increased morbidity (this is 
to say higher probability of hospitalisation, pneumonia and sepsis) (5). 
It is important to stress that  P. aeruginosa infections are difficult to treat because of the 
bacteria’s intrinsic resistance to many antibiotics, owing to its low outer membrane permeability, and 
its ability to acquire new resistance mechanisms during antibiotic treatment. P. aeruginosa’s broad 
spectrum of resistance relies on a wide range of different mechanisms, which are either encoded in its 
own chromosome or on plasmids. Resistance to most penicillins is produced by constitutive or 
inducible b-lactamases. They bind the b-lactam molecules much stronger than the penicillin binding 
proteins (PBP) and hydrolyse them by opening the b-lactam cycle. Secondly, P. aeruginosa is also 
4capable of modifying the PBF. Lastly it can use an efflux system “Mex-AB-Opr M”, which is 
expressed constitutively to expulse the b-lactam molecule out of the cell (7).”Mex-AB-OprM” is part 
of five efflux systems, which are constructed on the same model, by P. aeruginosa. They are made out 
of three different proteins, which work together. The first, an inner membrane protein, acts as a proton 
motor pump. The second, a periplasmic protein, links the first to the third component of the system, 
which is an outer membrane protein acting as an efflux porin. It’s important to stress the fact that each 
efflux system is able to accommodate compounds structurally unrelated, such as antibiotics of 
completely different classes, consequently inducing multiple resistance profiles (8). 
The resistance to third and fourth generation cephalosporins is based on the same mechanisms, 
except for the fact that the efflux system dealing with fourth generation cephalosporins is slightly 
different and its expression is only inducible. It is named “Mex-CD-Opr J”. The resistance to 
carbapenems, imipenem and meropenem, is mainly due to the loss of a specific outer membrane 
protein (porin) called OprD, a highly selective permeation pathway (9). Resistance to quinolones is 
also mediated by several mechanisms: three out of the four efflux systems can expulse these molecules, 
the constitutive “MexAB-M”, and the inducible ”MexCD-J” and “MexEF-N”. Their activation usually 
precedes the selection of a mutation of the DNA gyrase, which is the quinolone target (8). 
Aminoglycosids are rendered ineffective either by mutation of the ribosomal 30S gene, which encodes 
the antibiotic target protein; or by the constitutive expression of the efflux system “Mex XY” as well as 
by the plasmid-encoded enzymatic activity of acetylation, phosphorylation or adenylation of the 
antibiotic (1,7). 
Finally, resistance to macrolids is due to the efflux system “MexCD-J” and resistance to TMP-S to 
three of the pomps “MexAB-M”, “MexCD-J” and “Mex EF-N”. 
 
In conclusion this opportunistic bacteria, mainly responsible for nosocomial infections in 
debilitated patients, not only produces a number of cell-associated or extracellular virulence factors 
engaged in colonisation and tissue invasion, but also a wide variety of ingenious antibiotic resistance 
mechanisms which makes it a major therapeutic challenge. 
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B) P. AERUGINOSA  BACTEREMIA 
 
 
In spite of the fact that P. aeruginosa was recognized as a human pathogen in 1890 already, by 
Charing, it was not until the 1950’s that physicians started to show a growing interest in P. aeruginosa 
bacteremia. Indeed Forkner noted in 1958 that “only scattered reports are available” describing P. 
aeruginosa septicemia and it’s response to contemporary antimicrobial agents (10). From thereon the 
number of publications has been rising rapidly. Several important reasons explain this phenomenon, 
which we will now review. 
Mortality is certainly one of the reasons which led to an increasing attention towards P. 
aeruginosa bacteremia in the 1950’s. Indeed the numbers are stunning: mortality reached 84% in a 
review by Curtin in 1961 (11). Nowadays death still occurs in one out of two patients (12), despite the 
fall in mortality noted in the 1970’s, probably linked to the introduction of two potent anti-
pseudomonal drugs in the late 60’s, gentamicin and carbenicillin (figure 1). In the University Hospital 
of Geneva the mortality during the 1989-1998 period was found to be 25%. 
 
 
Figure 1. Mortality linked to P. aeruginosa bacteremia 
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6The rapidly rising incidence of P. aeruginosa bacteremia in the 60’s and 70’s has now placed it 
second amongst the Gram-negative bacteremia after E. coli (26);  with a prevalence ranging from 1,8 to 
4 ‰ (14,12). In the University Hospital of Geneva, the prevalence was found to be of 1‰ admissions 
and P. aeruginosa was the third most frequent cause of Gram negative bloodstream infection (1989 to 
1998) (average 5,4% of all bacteremia per year) (figure 2). This is partly attributable to ecologic 
changes in the normal microflora of the human body provoked by the use of broad spectrum 
antimicrobial agents (11). It is also attributable to the improved management of many severe diseases 
leading to prolonged survival of patients to a point where their resistance to bacterial infections is 
greatly impaired. The larger use of more aggressive chemotherapy, radiotherapy, radical surgery and 
any instrumentation is also an important factor. Finally it has been mentioned that the emergence of 
AIDS in the 80’s contributed to increase the rate of P. aeruginosa bacteremia (14) 
 
 
Figure 2. Bacteremia at the University Hospital of Geneva 
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7towards higher hospital costs and a higher rate of secondary bacteremia amongst patients infected by P. 
aeruginosa (16).   
As mentioned before, P. aeruginosa is an increasingly prevalent nosocomial pathogen, but it is 
also an opportunistic one, making a rather specific group of patients at hight risk to develop a P. 
aeruginosa bacteremia. Nowadays, what was previously an event occurring in the very young or very 
old, most often affects middle age patients. As mentioned earlier, this evolution probably reflects the 
advances in medico-technical support, allowing prolonged survival of highly susceptible, critically ill 
patients such as patients with cancer, transplants, or burns (17). The average age found in most of the 
latest articles is 54 years  with a predominance of men (14). 
Most authors agree on a certain number of risk factors predisposing to P. aeruginosa 
bloodstream infections. The exposure to antibiotics up to four weeks before the event is found in 87% 
of patients (18). Usage of vascular catheters, urinary catheters and endotracheal intubation, present in 
77%, 50% and 25 % respectively, have also been found to be risk factors in that they disrupt the 
integrity of the normal physical barriers, such as the epidermis or mucous membranes, and represent 
foreign bodies easily colonized by P. aeruginosa. Surgery, described in 34% of cases, also predisposes 
to P. aeruginosa bacteremia by the rupture of the physical barrier. Systemic corticotherapy, 
chemotherapy and neutropenia, described in 37%, 35% and 25% respectively, all contribute to immune 
deficiency, which is favorable to the occurrence of P. aeruginosa bacteremia. Finally, it was shown 
recently that secondary bacteremia developed significantly more often in patients infected by P. 
aeruginosa, in whom antibiotic resistance emerged (16). 
The vast majority of patients who present a P. aeruginosa bacteremia have a severe underlying 
disease, most often cancer (29%), or a chronic disease (11%), such as diabetes, renal failure, cirrhosis, 
heart failure, chronic pancreatitis or COPD (14). As the proportion of P. aeruginosa bacteremia in 
patients with cancer has been growing recently, attention has been focused on this particular group of 
patients, unveiling the fact that hematological cancers (16% including leukemia and malignant 
lymphoma ) are more common than solid tumors (13%) (14). Amongst hematological cancers the most 
frequent is leukemia whereas amongst the solid tumors, genitourinary cancers predominate (19). More 
recently, attention has turned towards solid organ transplantation (lung, kidney, liver, pancreas), and 
AIDS, as these have become important underlying diseases in patients developing P. aeruginosa 
bacteremia (14). 
8The usual path that leads to bacteremia starts by the patient being colonized. Then local 
infection occurs before the bacteria finally disseminates and causes a systemic illness. Unfortunately, it 
is not only almost impossible to predict the timing of these events but the source of the bacteremia 
frequently remains unknown (38%) (14). In the 60’s, the most important identified primary site was the 
genitourinary tract (11). Nowadays, it has changed to pneumonia, owing to the greater awareness of the 
danger of urinary tract instrumentation, especially the use of urinary catheters and to improved, as well 
as prolonged respiratory support in severely ill patients (22% of urinary tract infections versus 48% of 
pneumonias in a recent study by Kuikka) (17). Vascular catheters are also important primary sites of 
infection (16%), as well as the digestive tract (deep abscesses 7%, pancreatitis 6%, peritonitis 6%, 
cholangitis or cholecystitis 5%) (14). 
Unfortunately for the clinician there are no characteristic clinical features differentiating P. 
aeruginosa bacteremia from bacteremia due to other pathogens. The signs and symptoms range from 
fever ( 94%) (19) to septic shock (31-33%) (17-19) and rarely intravascular coagulation (0,5-11%) (19-
17). The typical skin lesion “Ecthyma Gangrenosum” (a skin infarction progressing to large ulcerated 
gangrenous lesions, characterized histologically, by a bacterial invasion of vascular walls with minimal 
inflammatory infiltrate) seems to be a terminal sign. Prompt institution of appropriate antimicrobial 
therapy at the onset of the bacteremia accounts for the fact that such lesions are nowadays only rarely 
seen. The last mentions of this sign in the literature were 3% in 1976 (17), and 0,5% in 1985 (19). 
Due to the high associated mortality, clinicians who deal with P. aeruginosa bacteremia are 
necessarily interested in establishing prognostic factors. Therefore, a number of studies have tried to 
determine and to validate such factors (12,14,17,23). In summary, receiving an inappropriate definitive 
antimicrobial therapy, presenting as a septic shock, having had a pneumonia as P. aeruginosa primary 
site of infection; having a severe underlying disease and being hospitalized in a surgical or ICU ward 
are all associated with a poor outcome. A higher risk of fatal outcome has also been noted in patients 
infected by P. aeruginosa and in whom resistance emerged (16). On the contrary, patients with high 
levels of antibodies against cytotoxins or the LPS have a better outcome (23). Neutropenia remains a 
subject of controversy as to it’s influence on the patient’s outcome; indeed some authors associate it 
with an increased mortality rate, whereas others do not confirm any significant impact on survival 
(21,14). 
The choice between using an antipseudomonal monotherapy (antipseudomonal penicillin or 
fourth generation cephalosporin, carbapenems or ciprofloxacine) or a combination therapy 
9(traditionally a beta-lactam or carbapenem, combined with an aminoglycoside or ciprofloxacine) to 
treat an episode of P. aeruginosa bacteremia has also remained a controversy for many years. The idea 
of combining a beta-lactam and an aminoglycoside is based on in vitro synergistic results in the late 
seventies (2). In 1989, a prospective clinical study including 200 consecutive cases of P. aeruginosa 
bacteremias by Hilf et al. (21) supported the use of a combination therapy (simultaneous use of an 
aminoglycoside and a beta-lactam agent) rather than a monotherapy. Survival was indeed improved for 
the total patient study group and certain subgroups (patients with pneumonia as the primary site of 
infection; patients with bacteremia of nosocomial origin and critically-ill patients). More recently, 
Leibovici et al. in their prospective study on Gram-negative bacteremia in non-neutropenic patients 
(24), noted a trend towards a reduction of mortality in patients presenting a P. aeruginosa bloodstream 
infection when treated with a combination of a beta-lactam and an aminoglycoside. Possible 
explanations for this trend could be the avoidance of an inappropriate initial therapy against a resistant 
P. aeruginosa bacteremic strain or the selection during treatment of a resistant strain. Monotherapy 
regimens were indeed shown to have unacceptable failure rates when treating patients with P. 
aeruginosa pneumonia and the principle cause of failure was development of resistance during therapy 
(1). Theoretically the use of an empirical combination therapy before the results of the susceptibility 
tests are known should reduce the risk of failure, but this remains to be proven. As a reminder, P. 
aeruginosa is the most common Gram-negative pathogen isolated from patients receiving inadequate 
antimicrobial treatment (25).  
 
Finally, it is important to keep in mind that P. aeruginosa bacteremia is not a rare infection, and 
that it is linked with a high mortality rate as still up to half of the patients die. The choice of an 
antimicrobial therapy is not only limited by the small number of antibiotics with an antipseudomonal 
activity but is made even more difficult by the ease with which resistant strains can be selected during 
therapy. Taking into account the fact that an inadequate definitive therapy is associated with a poor 
outcome, we undertook, at the University Hospital of Geneva, a large retrospective study on P. 
aeruginosa bacteremia. Our study was designed to address three controversial issues on P. aeruginosa 
bacteremia:  
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(1) Does exposure to antibiotics before the bacteremic event influence the resistance profile                     
of the bacteremic strains ?  
(2) Does the adequacy of both empiric, and definitive therapy impact on mortality ? 
(3) Does the use of a combination of two antipseudomonal antibiotics during empirical and/or 
definite therapy improve survival ? 
11
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INTRODUCTION  (VERSION FRANÇAISE) 
 
A) MICROBIOLOGIE 
 
 
           Pseudomonas aeruginosa (en latin : aeruginosus signifiant recouvert de rouille) est un des 
membres de la famille des Pseudomonaceae. Ce bâtonnet Gram négatif est mobile, aérobie et produit 
une odeur caractéristique  de raisin, en culture. C’est un germe ubiquitaire, que l’on retrouve partout, 
mais de manière privilégiée dans les milieux humides ou aqueux, tels les sols, les plantes, les végétaux 
(p.ex. les salades). En milieu hospitalier, on peut le mettre en évidence aussi bien dans les ventilateurs, 
les bassins de physiothérapie, les lavabos, que les produits de nettoyage et les plantes d’ornement. 
P. aeruginosa  est un pathogène opportuniste, infectant de manière presque exclusive les 
patients immunocompromis, par exemple neutropéniques, ventilés ou très gravement malades. En fait 
cette bactérie est décrite comme le prototype du germe hospitalier et est responsable d’un nombre 
important d’infections nosocomiales diverses et pouvant être sévères. C’est d’une part, un des germes 
le plus fréquemment retrouvé dans les cas de pneumonies associées à l’emploi d’une ventilation 
mécanique; d’autre part, il est responsable d’infections urinaires et de bactériémies; il est moins 
fréquemment associé à des infections de plaies chirurgicales ou de brûlures, d’otites malignes externes 
chez le patient diabétique, d’infections de la sphère gastro-intestinale tel qu’abcès intra-abdominal, 
cholangite, péritonite, pancréatite; enfin d’ostéomyélite, de kératite (panophtalmite) et finalement 
d’endocardite chez les patients toxicomanes. 
P. aeruginosa doit son pouvoir pathogène à la production d’un nombre important de facteurs de 
virulence, qui sont soit directement associés  à sa cellule, tels le flagelle, les pilli, le LPS et le biofilm, 
soit excrétés dans le milieu extra-cellulaire telles les diverses enzymes à activités spécifiques. Plus de la 
moitié des isolats cliniques produisent un pigment fluorescent nommé pyocyanine, qui donne aux 
colonies une couleur verdâtre. Le flagelle polaire, les pilli, et le LPS sont tous implantés dans la 
membrane externe de la cellule. Les premiers sont non seulement responsables de la mobilité de la 
cellule, mais également de son adhésion aux muqueuses, alors que le dernier, aussi appelé endotoxine, 
active la réaction inflammatoire de l’hôte. Dans certaines conditions, P. aeruginosa, produit une 
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matrice extra-cellulaire appelée biofilm. Celle-ci est essentielle à la colonisation des matières inertes et 
interagirait également avec les cellules épithéliales. Dans le cas particulier des patients présentant une 
mucoviscidose, les souches pulmonaires de P. aeruginosa forment des colonies mucoides qui 
produisent un biofilm très épais, qui consiste en une structure répétée d’acide manuronique et 
guluronique, se nommant alginate. Ces souches mucoides sont connues pour être particulièrement 
résistantes à la phagocytose et moins sensibles à l’action des antibiotiques. Comme mentionné ci-
dessus, P.aeruginosa, produit aussi un certain nombres de facteurs de virulence excrétés dans le milieu 
environnant: les protéases, principalement l’élastase et la protéase alcaline, jouent un rôle important 
dans l’invasion tissulaire, par exemple en dégradant les fibres d’élastine du tissus pulmonaire, ou en 
détruisant la laminine et l’élastine des membranes basales, ou encore les connections intercellulaires au 
niveau de la cornée ou de l’épithélium respiratoire, par exemple. Les hémolysines, c’est-à-dire, les 
rhamnolipides et la phospholipase C, contribuent également à la destruction tissulaire grâce à leur 
action cytotoxique et à leur pouvoir  de dégradation du surfactant pulmonaire. Ces enzymes travaillent 
de manière synergique: les rhamnolipides solubilisent les lipides membranaires libérant les 
phospholipides, qui sont hydrolysés secondairement par la phospholipases C. Quant à l’Exotoxine A, 
elle joue un rôle dans la toxicité systémique de P. aeruginosa, en inhibant la synthèse des protéines, à 
la manière de la toxine diphtérique. De plus, P. aeruginosa, comme d’autres Gram négatif, est pourvu 
d’un système spéciale de sécrétion appelé “ type III secretion system”, qui lui permet d’injecter des 
toxines directement dans la cellule hôte adjacente. Ce système est composé de trois protéines 
fonctionnant de manière coordonnée: le complexe de sécrétion et de translocation, ainsi que les 
diverses toxines, qui se nomment, dans le cas de P. aeruginosa, ExoS, ExoT, ExoU et ExoY. 
Récemment, il a été mis en évidence, que l’expression de ce système, au sein des isolats cliniques, est 
corrélée avec une augmentation de la morbidité et de la mortalité clinique (5). 
 La production de ces diverses enzymes extra-cellulaires est finement régulée et coordonnée par un 
système de signalisation intercellulaire modulé par la densité cellulaire (le phénomène de «quorum-
sensing»). 
Les infections à P. aeruginosa sont notoirement connues pour être difficile à traiter, en raison 
de la résistance intrinsèque de la bactérie à de nombreux antibiotiques, elle-même secondaire à la faible 
perméabilité de sa membrane externe et à son extraordinaire capacité d’acquérir de nouveaux 
mécanismes de résistance, en cours d’antibiothérapie. P. aeruginosa doit son large spectre de résistance 
à différents mécanismes, qui sont soit codés au niveau de son propre chromosome, soit sur des 
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plasmides. La résistance aux beta-lactams est principalement médiée par l’expression constitutive ou 
inductible de beta-lactamases. Celles-ci lient la molécule beta-lactam plus fortement que les PBP 
(penicillin binding protein), c’est-à-dire les protéines cibles de l’antibiotique et l’hydrolysent. De plus, 
P. aeruginosa est également capable de modifier la PBP. Enfin, la bactérie peut utiliser un système 
d’efflux «Mex-AB-OprM», qui est exprimé de manière constitutive, afin d’expulser la molécule de 
beta-lactam hors de la cellule.«Mex-AB-Opr M» fait partie d’un ensemble de cinq systèmes d’efflux, 
construits par P. aeruginosa sur le même modèle. Ils sont tous composés de trois protéines, qui 
fonctionnent de manière coordonnée. La première est une protéine s’insérant dans la membrane 
cytoplasmique et qui joue le rôle de pompe à proton (transporteur). La deuxième, une protéine 
périplasmique, relie la première à la troisième, qui est une protéine de la membrane externe, formant 
des pores et permettant le rejet des molécules pompées. Il est important de souligner, que chaque 
système d’efflux est capable d’accommoder des molécules structurellement non apparentées, tels des 
antibiotiques de différentes classes, entraînant, par conséquent, l’apparition de résistances multiples. 
La résistance aux troisième et quatrième générations de céphalosporines se base sur les mêmes 
mécanismes. Néanmoins, le système d’efflux expulsant les céphalosporines de quatrième 
génération,«Mex-CD-Opr J », est légèrement différent et son expression n’est qu’inductible. La 
résistance aux carbapénèmes, imipenem et méropenem, est essentiellement due à la perte d’une 
protéine spécifique de la membrane externe, une porine appelée OprD, qui constitue un transporteur 
hautement sélectif. 
 La résistance aux quinolones est également médiée par divers mécanismes: trois des cinq pompes à 
efflux sont capables d’expulser ces molécules hors de la cellule:«Mex-AB-M», dont l’expression est 
constitutive et «Mex-CD-J», ainsi que «Mex-EF-N», dont l’expression est inductible. Leur activation 
précède généralement la mutation de la protéine cible des quinolones, c’est-à-dire la DNA gyrase. 
L’action des aminoglycosides est rendue caduque, soit par la mutation du gène codant pour la protéine 
30S ribosomale, protéine cible de cette classe d’antibiotique, soit par l’expression constitutive de la 
pompe à efflux «Mex XY», soit, enfin, par l’acétylation-phosphorylation ou l’adélylation de 
l’antibiotique, par une enzyme codé au niveau d’un plasmide. Pour terminer, signalons que la 
résistance aux macrolides est due à l’expression du système «Mex-CD-J» et celle aux TMP-S à trois 
pompes «Mex-AB-M», «Mex-CD-J» et «Mex-EF-N». 
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En résumé, cette bactérie opportuniste, principalement responsable d’infections nosocomiales, 
chez les patients immunocompromis, produit non seulement des facteurs de virulence associés à sa 
cellule ou excrétés dans le milieu extra-cellulaire, responsables de la colonisation et de l’invasion 
tissulaire, mais également un nombre important de mécanismes de résistance aux antibiotiques, ce qui 
en fait un défit thérapeutique majeur. 
 
          B) BACTERIEMIE A  P. AERUGINOSA 
 
Malgré le fait que P. aeruginosa ait été reconnu comme pathogène humain en 1890 déjà, par un 
certain Charing, il faut attendre jusqu’en 1950 pour que le monde médical commence à s’intéresser 
sérieusement à cette bactérie. En 1958, Forkner notait qu’il n’existait que peu de rapports décrivant les 
bactériémies à P. aeruginosa. Dès lors, le nombre de publications n’a fait qu’augmenter. Plusieurs 
raisons importantes sont à la base de cet intérêt croissant. Nous allons en faire ici une revue.  
En 1950, c’est la mortalité liée à la bactériémie à P.aeruginosa, qui est à l’origine de l’attention 
portée au sujet. Effectivement les chiffres sont alors impressionnants: le taux de mortalité pouvant 
s’élever jusqu’à 84% (revue par Curtin en 1961). De nos jours, près de la moitié des patients atteints 
peut encore décéder des suites de leur infection, malgré la baisse de la mortalité notée dans les années 
70 et imputable à l’introduction de deux antibiotiques à action antipseudomonale: la gentamicine et la 
carbenicilline. A l’Hôpital Cantonal Universitaire de Genève, durant la période allant de 1989 à 1998, 
la mortalité s’élevait à 25%. 
Les bactériémies à P.aeruginosa, se situent actuellement au deuxième rang des bactériémies à 
Gram négatif après celles à E. coli, avec une prévalence allant de 1,8 à 4‰, suivant les articles. A 
l’Hôpital Cantonal Universitaire de Genève, durant la période allant de 1989 à 1998, la prévalence était 
de 1‰, admissions et P. aeruginosa tenait le troisième rang des bactériémies à Gram négatif, avec une 
fréquence annuelle de 5,4%. Ceci reflète les changements apportés au sein de la microflore humaine, 
par l’utilisation de plus en plus fréquente d’antibiotiques à large spectre. Elle est aussi attribuable à 
l’amélioration de la prise en charge de patients gravement malades, dont la survie est prolongée au 
point ou leurs mécanismes de défense immunitaire sont compromis. Enfin, l’utilisation plus fréquente 
de chimiothérapie agressive, de radiothérapie et de chirurgie radicale sont également responsables de 
cette incidence sans oublier l’émergence du syndrome d’immunodéficience acquise, dans les années 
1980. 
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Un autre point d’importance, responsable de l’intérêt croissant pour les bactériémies à P. 
aeruginosa est celui de la résistance de la bactérie aux antibiotiques. Le nombre d’antibiotiques actifs 
contre cette bactérie est encore restreint et l’est d’autant plus que la bactérie est capable d’acquérir de 
nouveaux méchanisme de résistances, en cours d’antibiothérapie. Dans ce sens, une étude récente a 
confirmé que l’administration d’imipenem, de ceftazidime et de ciprofloxacine, tous de puissants 
agents antipseudomonaux, est associé à un risque important d’émergence de résistance à ces mêmes 
antibiotiques. De plus, cette émergence de résistance, en cours de thérapie, parmi les patients infectés 
par P. aeruginosa, est associée à un séjour intra-hospitalier prolongé, à une tendance vers 
l’augmentation des coûts et à un risque de bactériémie secondaire. 
Comme mentionné précédemment, P. aeruginosa n’est pas seulement un pathogène 
nosocomial, mais également un opportuniste, rendant certaines catégories de patients plus à risque que 
d’autre de présenter un épisode de bactériémie à P. aeruginosa. Ce qui était un événement touchant soit 
les patients très jeunes ou très âgés, intéresse les progrès médico-techniques, qui permettent de 
prolonger la survie de patients gravement malade, par exemple transplantés ou atteints d’un cancer. 
La plupart des auteurs s’accordent sur le fait qu’il existe un certain nombre de facteurs de risque 
prédisposant à la survenue d’un épisode de bactériémie à P. aeruginosa: l’exposition à des 
antibiotiques, dans les quatres semaines préalables à l’épisode de bactériémie, est relevé chez 87% des 
patients; l’utilisation de cathéters endoveineux ou urinaires et l’intubation endotrachéale sont retrouvés 
chez 77%, 50% et 25% des patients respectivement. Leur mécanisme de facilitation repose sur  la 
rupture de l’intégrité de la barrière physique de protection, tels les épithéliums ou les muqueuses, et la 
colonisation facilitée des matières inertes. Dans le même ordre d’idée, les gestes chirurgicaux, 
également relevés chez 34% des patients, prédisposent aussi à une bactériémie à P. aeruginosa. 
L’utilisation de corticoïdes systémiques, la chimiothérapie, et la neutropénie décrits dans 37%, 35% et 
25% des patients respectivement, tous contribuent à une certaine déficience immunitaire favorable à la 
survenue d’une bactériémie à P. aeruginosa. Finalement, un article récent a démontré que les patients 
infectés par une souche de P. aeruginosa, chez qui une émergence de résistance aux antibiotiques  avait 
été notée, présentaient significativement plus d’épisodes de bactériémies secondaires. 
La majorité des patients présentant un épisode de bactériémie à P. aeruginosa sont sujets à 
d’importantes co-morbidités. Le plus souvent il s’agit de cancers (29%) ou d’une maladie chronique, 
telle le diabète, l’insuffisance rénale chronique, la cirrhose hépatique, l’insuffisance cardiaque, la 
pancréatite chronique ou la bronchopneumopathie chronique obstructive. Les cancers de la sphère 
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hématologique sont plus nombreux que les cancers touchant un organe solide (16% versus 13% des 
patients) et parmi les premiers, on trouve surtout des leucémies et moins des lymphomes; parmi les 
seconds, des tumeurs de la sphère uro-génitale prédominent. Notons, pour terminer, que les patients 
transplantés (poumons, reins, foie, pancréas) et les patients atteints du syndrome d’immunodéficience 
acquise forment des nouvelles catégories de patients à risque.  
L’enchaînement des événements, qui mènent à une bactériémie, commence par la colonisation 
du patient. Une infection localisée survient ensuite, avant la dissémination systémique de la bactérie. 
Malheureusement, il est impossible de prédire le moment exact de ces différents événements et souvent 
le site primaire d’infection demeure inconnu (38% des cas). Dans les années 1960, le site primaire 
d’infection le plus souvent retrouvé était urinaire ; actuellement il est pulmonaire (22% des patients 
présentaient une origine urinaire et 48% une pneumonie, dans une étude récente). Ce changement est 
vraisemblablement secondaire à la prise de conscience du risque encouru lors d’instrumentation 
urinaire, ainsi qu’à la prolongation de la ventilation mécanique chez les patients sévèrement malades. 
Les cathéters endovasculaires sont également d’importants sites d’infection (16% des cas), ainsi que la 
sphère digestive (abcès intra-abdominal 7%; pancréatite 6%; cholangite ou cholecystite 5%). 
Il faut déplorer l’absence de caractéristique clinique permettant de différencier une bactériémie 
à P. aeruginosa, d’une bactériémie due à un autre germe. Les symptômes et signes retrouvés dans la 
littérature s’échelonnent entre la fièvre (94% des cas) et le tableau de choc septique (ce dernier retrouvé 
dans 31% des cas en 1976 et 33% des cas en1985). Rarement il est fait mention d’une coagulation 
intraveineuse disséminée (11% en 1976 et 0,5% en 1985). La lésion cutanée typique nommée «ecthyma 
Gangrenosum» se caractérisant histologiquement par une invasion bactérienne de la paroi vasculaire, 
avec une réaction inflammatoire minime, progressant vers la nécrose cutanée et macroscopiquement 
visible sous forme de lésions ulcérées, semble être un signe terminal. L’introduction rapide d’une 
antibiothérapie explique probablement pourquoi cette lésion n’est plus guère retrouvée (3% de patients 
en 1976 et 0,5% en 1985, date de sa dernière mention dans la littérature). 
Le clinicien qui traite une maladie aussi grave qu’une bactériémie à P. aeruginosa est 
nécessairement intéressé à établir des facteurs de pronostic, c’est pourquoi un certain nombre d’études 
ont été effectués, afin de les déterminer et les valider. En résumé, les facteurs de mortalité accrue sont 
les suivants: recevoir une antibiothérapie définitive inapproprié, une présentation initiale en choc 
septique, une bactériémie secondaire à une pneumonie à P. aeruginosa, des comorbidités sévère, enfin 
une hospitalisation en milieu de soins intensif de chirurgie. Un risque plus élevé de mortalité a 
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également été mis en évidence chez des patients infectés par des souches de P. aeruginosa devenues 
résistantes. Par contre, un risque moindre a été relevé chez des patients possédant de hauts taux 
d’anticorps contre les cytotoxines ou contre le LPS. De manière surprenante, la neutropénie demeure 
un sujet de controverse quant à son influence sur le pronostic final du patient; effectivement certains 
auteurs l’associent à une mortalité accrue, d’autres ne trouvent pas d’association significative avec 
l’évolution clinique. 
Le choix entre l’emploi d’une monothérapie (généralement une pénicilline à effet 
antipseudomonal, une céphalosporine de quatrième génération,une carbapeneme, la ciprofloxacine) 
versus une combinaison de deux antibiotiques à effet antipseudomonal (traditionnellement une beta-
lactam ou une carbapénème associé avec un aminoglycoside ou la ciprofloxacine) pour traiter un 
épisode de bactériémie à P. aeruginosa est un sujet de controverse depuis de nombreuses années. L’idée 
de combiner une B-lactam et une aminoglycoside est basée sur l’effet synergique obtenu in vitro, lors  
d’essai fait dans les années 1970. En 1989, une étude clinique prospective effectuée par Hilf et al 
soutenait l’emploi d’une bithérapie (beta-lactam plus aminoglycoside), versus une monothérapie pour 
traiter une bactériémie à P. aeruginosa. Effectivement la survie de l’ensemble des patients de l’étude 
était améliorée. Ceci était particulièrement vrai pour certains sous-groupes, c’est-à-dire, les patients 
présentant une pneumonie comme site d’infection primaire, les patients dont l’épisode de bactériémie 
était nosocomiale et le groupe de patients sévèrement atteints. 
Plus récemment, Leibovici et  al ont mis en évidence, une diminution de la mortalité, parmi les 
patients non neutropénique, traités pour une bactériémie à P. aeruginosa, par une association de beta-
lactam et d’aminoglycosides. Les raisons pouvant expliquer ce pronostic plus favorable sont, d’une 
part, le fait d’éviter d’employer une antibiothérapie inappropriée contre un germe résistant, d’autre part 
la réduction du risque de sélection d’un mutant résistant en cours de traitement. En 1992,une étude par 
Dunn et al. met en évidence un taux d’échec thérapeutique inacceptable parmi les patients traités par 
monothérapie pour une pneumonie à P. aeruginosa; la raison principale incriminée étant l’émergence 
de résistances parmi les souches bactériennes durant le traitement. Pour rappel, P. aeruginosa est le 
Gram négatif le plus fréquemment isolé chez les patients recevant une antibiothérapie inadéquate. 
  
Pour terminer, il est important de rappeler les éléments suivants: la bactériémie à P. aeruginosa 
n’est pas un événement rare et la mortalité qui lui est  associée est encore élevée, puisque certains 
articles rapportent que la moitié des patients atteints meurent encore de nos jours des suites de leur 
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infection. Le choix d’une antibiothérapie n’est pas seulement limité par le petit nombre d’antibiotiques 
à disposition ayant un effet antipseudomonal, mais est également rendu difficile par la facilité avec 
laquelle des souches résistantes sont sélectionnée durant une antibiothérapie. Et il est d’autant plus 
crucial de faire le bon choix, compte tenu du fait que l’administration d’une antibiothérapie définitive 
inadéquate est associée à un très mauvais pronostic. Au vu de l’importance du sujet, nous avons donc 
effectué une étude rétrospective sur les bactériémies à P. aeruginosa. Notre étude a pris place à 
l’Hôpital Cantonal Universitaire de Genève et s’est focalisée sur trois points encore débattus: 
 
1) Est-ce que l’exposition à des antibiotiques à effet antipseudomonal, préalablement à l’épisode 
de bactériémie, influence le profil de résistance des souches bactériémiques? 
2) Est-ce que l’adéquacité des traitements empiriques et définitifs  influence la mortalité? 
3) Est-ce que l’utilisation d’une antibiothérapie combinée comme traitement empirique ou définitif 
influence la survie? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Previous Antibiotic Therapy and P. aeruginosa • CID 2001:33 (1 December) • 1859
M A J O R A R T I C L E
Influence of Previous Exposure to Antibiotic
Therapy on the Susceptibility Pattern of
Pseudomonas aeruginosa Bacteremic Isolates
E. Boffi El Amari,1 E. Chamot,2 R. Auckenthaler,3,a J. C. Peche`re,1 and C. Van Delden1
1Department of Microbiology and Genetics and 2Institut of Social and Preventive Medicine, University of Geneva, and 3Laboratory of Clinical
Microbiology, University Hospital of Geneva, Geneva
Many patients who present with Pseudomonas aeruginosa bacteremia have been previously exposed to anti-
biotics. To assess whether resistance of bacteremic strains to antipseudomonal antibiotics (piperacillin, cef-
tazidime, imipenem, ciprofloxacin, or aminoglycosides) is associated with previous exposure to these drugs,
a case-control study including 267 cases of P. aeruginosa bacteremia was conducted. Twenty-five percent of
the episodes had been preceded by the exposure to an antipseudomonal antibiotic. Eighty-one strains were
resistant to at least 1 antibiotic; 186 were susceptible to all drugs. Via univariate analysis, the risks of resistance
to ceftazidime and imipenem were found to be significantly associated with previous receipt of these agents.
Using multivariate analysis, exposure to any antipseudomonal antibiotic as a monotherapy was found to be
associated with an increased risk of subsequent resistance to itself (odds ratio, 2.5; ). Therefore,Pp .006
clinicians should avoid readministering previously prescribed antibiotics when initiating empiric therapies for
possible P. aeruginosa bacteremia, especially when they have been given as monotherapies.
Pseudomonas aeruginosa is a leading cause of nosocom-
ial bloodstream infections, ranking third among gram-
negative bacteria, after Escherichia coli and Klebsiella
species [1]. Despite improvement in recent years, the
prognosis of P. aeruginosa bacteremia remains poor,
with case-fatality rates of 20% [2–5]. Factors that
delay therapeutic improvements are the rapid course
of the disease, the scarcity of antibiotics with antipseu-
domonal activity, and the ease with which the bacte-
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rium acquires new resistances during antibiotic ther-
apy [6]. As a result of this capacity to rapidly acquire
resistance mechanisms, P. aeruginosa bacteremia fre-
quently follows other infections treatment with antibiotic
regimen that include antipseudomonal drugs.
Because the symptoms of P. aeruginosa bacteremia
are nonspecific, the initial antibiotic therapy for pos-
sible P. aeruginosa bacteremia is almost always empir-
ical, with a pending identification of the responsible
pathogen and an unknown antibiotic resistance profile.
Inappropriate antibiotic treatment of bacteremia is as-
sociated with a significantly poorer outcome [7]. It is
therefore important to determine whether recent ex-
posure to antibiotics with antipseudomonal activity in-
creases the risk of resistance of bacteremic strains to
these agents [3]. Answering this question would help
clinicians choose the most adequate empirical treat-
ment in clinical situations that include P. aeruginosa
bacteremia as a possible cause.
We identified 267 P. aeruginosa bacteremic events
that occurred at a tertiary-care hospital and conducted
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a case-control study to determine whether recent exposure to
antibiotics with antipseudomonal activity was associated with
an increased risk of resistance toward these drugs.
PATIENTS AND METHODS
This study took place at the Geneva University Hospital, Swit-
zerland, a 1000-bed tertiary-care teaching center that serves as
a first-line medical center for an urban population of ∼400,000
inhabitants and as a referral center for a larger population
coming from both Switzerland and nearby France.
Study design. We used the microbiology laboratory da-
tabase of the hospital to identify all inpatients that had had 1
or several blood cultures positive for P. aeruginosa from 1 Jan-
uary 1989 through 31 December 1998. Medical records were
reviewed for information on demographic characteristics, clin-
ical presentation of bacteremia, primary site of P. aeruginosa
infection, underlying medical conditions, immunosuppression
at the time of bacteremia, invasive procedures, laboratory re-
sults of antibiotic susceptibility, and recent antibiotic treatment
including an agent with antipseudomonal activity. An “episode”
of P. aeruginosa bacteremia was defined as a positive blood
culture with this pathogen. “Previous monotherapy” was de-
fined as a therapy that started within 30 days before the positive
blood culture, included only 1 of the antipseudomonal anti-
biotics used in our institution (piperacillin, ceftazidime, imi-
penem, ciprofloxacin, gentamicin, and amikacin), was admin-
istered for 148 h, and was stopped !15 days before the
bacteremia. “Previous combination therapy” was defined as fol-
lows: treatment was initiated within 30 days and stopped !15
days before the positive blood culture; it included the concom-
itant use for 48 h of a b-lactam antibiotic, and either an
aminoglycoside or ciprofloxacin, or the combination cipro-
floxacin plus aminoglycoside, with an exposure to a single drug
for no more than 48 h. All other patterns of antibiotic exposure
were classed in the “no previous treatment” group. In a first
analysis, “cases” were defined as episodes of bacteremia caused
by a strain of P. aeruginosa resistant to at least 1 antipseu-
domonal antibiotic and “controls” as episodes involving strains
susceptible to all 6 antibiotics. Three categories of exposure
were examined: any previous combination therapy, any pre-
vious monotherapy, and no previous therapy. In subsequent
analyses, cases were episodes caused by a strain resistant to 1
specified antibiotic, and controls were episodes caused by a
strain susceptible to that same antibiotic; hence, bacteremic
strains resistant to 2 antibiotics contributed more than once
to these analyses. Patients were considered exposed if they had
received the specified antibiotic either as a monotherapy or as
an agent included in a combination therapy.
Microbiology. A minimum of 2 pairs of blood cultures
was performed at the time of presumed bacteremia. P. aeru-
ginosa was identified at the laboratory of clinical microbiology
via standard clinical microbiology methods [8]. Antimicrobial
susceptibility was determined by disk diffusion methods ac-
cording to the recommendations of the National Committee
for Clinical Laboratory Standards (NCCLS) [9]. An isolate was
considered susceptible, intermediate, or resistant according to
the criteria of the NCCLS. The isolates with intermediate sus-
ceptibility were classified as resistant for analysis. No molecular
typing was performed.
Statistical analysis. We calculated crude ORs and exact
95% CI to evaluate the potential relation between previous
antipseudomonal therapy and resistance of the bacteremic
strain. Two-tailed Fisher’s exact tests were used for the com-
parison of proportions.
Multiple logistic regression was used to assess whether having
received a previous monotherapy or combination therapy in-
cluding a specific antipseudomonal agent were independent risk
factors for resistance of the bacteremic isolate to that same
agent. Because data were scarce, observations corresponding to
all 6 antibiotics were pooled in a stratified model. Therefore,
each episode of bacteremia contributed 5 times to the model
(1 stratum per antibiotic); variance estimates were adjusted to
reflect the resulting dependence among observations. Previous
monotherapy and combination therapy were forced in the
model; we further considered independent variables with P !
in univariate logistic regression (data not shown). To limit.2
the risk of overfitting, no interaction terms were tested. Re-
gression analyses were performed by STATA version 6.0 (STATA
Corporation).
RESULTS
Characteristics of bacteremic episodes. During the study pe-
riod, 273 P. aeruginosa bacteremic episodes occurred in 267
patients. Computerized microbiological data and medical re-
cords were available for all patients. Four patients had 2 in-
dependent episodes of bloodstream infections separated by
14–69 days, and 1 person had 3 episodes over a period of 50
days. We report here on the 267 initial episodes of P. aeruginosa
bacteremia.
The overall incidence of P. aeruginosa bacteremia at the Ge-
neva University Hospital was 1 per 1000 admissions (range per
year, 0.63‰–1.45‰). P. aeruginosa bacteremia accounted for
5.4% (range, 3.7%–7.6%) of all bloodstream infections. The
mean age of the patients was 59 years (range, 1 day to 93 years;
SD, 22 years), and approximately two-thirds were men (table
1). At the time of bacteremia, 32% of patients were hospitalized
in acute-care and 14% in chronic-care medical services, 17%
were in surgical wards, and 37% were in intensive care units
(medical and surgical). The most common sites of primary
infection were the respiratory and the urinary tracts; no source
Table 1. Univariate associations of clinical characteristics with resistance of Pseudomonas aeru-
ginosa in 267 patients.
Characteristic
Total no.
(%)
Resistance to
antipseudomonal agents
OR (95% CI) P
1 resistance
(cases; n p 81)
No resistance
(controls; n p 186)
Previous antipseudomonal therapya
No 201 (75.3) 55 146 — —
Yes 64 (24.0) 26 38 1.8 (0.96–3.4) .09
Monotherapy 54 (20.2) 22 32 1.8 (0.92–3.6) .07
Combination therapyb 10 (3.7) 4 6 1.8 (0.35–7.8) .47
Age, years
!65 132 (49.4) 44 88 — —
65 135 (50.6) 37 98 0.76 (0.43–1.3) .35
Sex
Male 195 (73.0) 59 136 — —
Female 72 (27.0) 22 50 1.0 (0.53–1.9) 1.0
Calendar time
1988–1992 126 (47.2) 27 99 — —
1993–1998 141 (52.8) 54 87 2.3 (1.3–4.1) .003
Ward
Medical acute care 84 (31.5) 18 66 — —
Other 183 (68.5) 63 120 1.9 (1.0–3.7) .03
Primary site(s) of infection
Unknown/other 142 (53.2) 38 104 — —
Respiratory 47 (17.6) 16 31 1.4 (0.64–3.0) .36
Urinary 46 (17.2) 20 26 2.1 (1.0–4.4) .04
Digestive 24 (9.0) 9 15 1.6 (0.58–4.4) .33
Vascular 17 (6.4) 3 14 0.59 (0.10–2.3) .56
Cutaneous 13 (4.9) 2 11 0.50 (0.05–2.4) .52
Clinical presentation
Fever/simple sepsis 183 (68.5) 48 135 — —
Severe sepsis 29 (10.9) 11 18 1.7 (0.68–4.2) .26
Shock 55 (20.6) 22 33 1.9 (0.94–3.7) .06
Underlying medical conditionc
No 34 (12.7) 11 23 — —
Yes 233 (87.3) 70 163 0.9 (0.39–2.2) .84
Immunological risk factor for infection
None of the following 203 (76.0) 64 139 — —
Neutropenia 48 (18.0) 10 38 0.57 (0.24–1.3) .16
Steroid treatment 18 (6.7) 7 11 1.4 (0.43–4.1) .60
Invasive procedures
None of the following 48 (18.0) 7 41 — —
Vascular catheter 205 (76.8) 68 137 2.9 (1.2–8.1) .01
Urinary catheter 150 (56.2) 50 100 2.9 (1.2–8.3) .02
Intubation 101 (37.8) 32 69 2.7 (1.0–7.5) .03
Drainage tube 57 (21.3) 17 40 2.5 (0.86–7.8) .10
Parenteral nutrition 38 (14.2) 14 24 3.4 (1.1–11.3) .02
Other 95 (35.6) 31 64 2.8 (1.1–7.8) .02
a Includes ceftazidime, piperacillin, imipenem, ciprofloxacin, an aminoglycoside, or some combination of these; 2 patients
had received a combination therapy with 2 antipseudomonal agents preceded or followed by a monotherapy with a third
agent.
b Two patients who had received monotherapy followed by combination therapy including other drugs were classified as
having received combination therapy.
c Malignancy, AIDS, diabetes, pancreatitis, respiratory dysfunction, heart disease, renal failure, severe nonpseudomonal
infection, or severe trauma.
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Table 2. Univariate analysis of therapies, including ceftazi-
dime, piperacillin, imipenem, ciprofloxacin, and aminoglycosides,
as risk factors for antibiotic-specific resistance in 267 bacteremic
strains of Pseudomonas aeruginosa.
Antipseudomonal
agent, included in
previous therapy
Resistance of the
bacteremic strain
to this agent
OR (95% CI) P
Yes
(cases)
No
(controls)
Ceftazidime
Yes 3 5 —
No 13 246 11.4 (1.6–64.7) .008
Piperacillina
Yes 3 6 —
No 26 231 4.4 (0.67–22.1) .06
Imipenema
Yes 11 25 —
No 30 186 2.7 (1.1–6.5) .02
Ciprofloxacin
Yes 0 9 —
No 15 243 0.0 (0.0–9.1) 1.0
Aminoglycoside
Yes 6 26 —
No 37 198 1.2 (0.39–3.4) .61
a One isolate was not tested against piperacillin, and 15 were not tested
against imipenem.
of bacteremia could be identified in about half the patients.
Severe sepsis was the initial manifestation of bloodstream in-
fection in 11% of episodes and shock in 22%. Approximately
233 (90%) of 267 patients had severe underlying medical con-
ditions: 91, malignancy (34%); 69, heart disease (26%); 58,
respiratory dysfunction (22%); 51, nonpseudomonal severe in-
fection (19%); 48, renal failure (18%); 29, diabetes (11%); 16,
AIDS (6%); 14, severe trauma (5%); and 12, pancreatitis (4%).
Immunosuppression was documented in 64 patients (24%) and
invasive procedure that increased the risk of bacteremia in 219
(82%).
Sixty-six patients (24.7%) had been exposed to an antibiotic
therapy active against P. aeruginosa (monotherapy, ;np 54
combination therapy, ; monotherapy followed by a com-np 8
bination therapy with 2 other agents, ; table 1) beforenp 2
the bacteremic event. Of these regimens, 36 included imipenem;
9, piperacillin; 9, ciprofloxacin; 8, ceftazidime; and 32, an ami-
noglycoside (table 2). Of the 267 P. aeruginosa blood isolates,
15 were not tested for susceptibility to imipenem and 1 isolate
was not tested for susceptibility to piperacillin. A total of 186
blood isolates (70%) were susceptible to all tested antibiotics,
35 (13%) were resistant to 1 antibiotic, 27 (10%) to 2 anti-
biotics, and 19 (7%) to 3 antibiotics. Forty-three isolates
(16%) were resistant to an aminoglycoside (gentamicin or ami-
kacin), 41 (15%) to imipenem, 29 (11%) to piperacillin, 16
(6%) to ceftazidime, and 15 (6%) to ciprofloxacin.
Univariate risk factors for resistance to 1 antipseudo-
monal agent. Patients who had been exposed to previous
therapy including an antipseudomonal agent were marginally
more likely to have experienced a P. aeruginosa bloodstream
infection with a strain resistant to 1 of the study antibiotics
than patient who had not been previously exposed (OR, 1.8;
95% CI, 1.0–3.4; ; table 1). Previous exposure to aPp .06
monotherapy was marginally associated with an increased risk
of resistance (OR, 1.8; 95% CI, 0.92–3.6; ). No statis-Pp .07
tically significant association was found between a previous
combination therapy and risk of resistance (OR, 1.8; 95% CI,
0.35–7.8; ). Bacteremia experienced between 1993 andPp .47
1998, hospitalization on other units than the acute-care medical
services, urinary source of infection, septic shock as clinical
mode of presentation ( ), and having experienced anPp .06
invasive procedure (except a drainage tube) were other factors
significantly associated with resistance to 1 antibiotic.
Crude risk of resistance to an antibiotic after exposure to
that same antibiotic. In univariate analysis, we did not at-
tempt to distinguish between situations where an antibiotic had
been received as a monotherapy or as part of a combination
therapy (too few patients had received any specific antibiotic
as part of a combination therapy). Previous exposure to cef-
tazidime was significantly associated with an increased risk of
resistance of the bacteremic isolate toward this antibiotic (OR,
11.4; 95% CI, 1.6–64.7; ; table 2). Similarly, previousPp .008
treatment with imipenem was significantly associated with an
increased risk of resistance toward itself (OR, 2.7; 95% CI,
1.1–6.5; ), and previous exposure to piperacillin wasPp .02
marginally associated with an increased risk of resistance (OR,
4.4; 95% CI, 0.67–22.1; ). In contrast, previous expo-Pp .06
sure to ciprofloxacin or an aminoglycoside was not associated
with an increased risk of resistance to themselves.
Average adjusted risk of resistance to an antibiotic after
exposure to that same antibiotic. In multivariate analysis
stratified for antipseudomonal agents, previous monotherapy
with an antipseudomonal antibiotic was independently asso-
ciated with an increased risk of subsequent resistance of the
bacteremic strain to that antibiotic (OR, 2.5; 95% CI, 1.3–4.8;
; table 3). The risk of subsequent resistance was notPp .006
significantly increased among patients who had received a com-
bination therapy (OR, 1.8; 95% CI, 0.55–5.6; ). How-Pp .34
ever, no significant difference was observed between combi-
nation therapies and monotherapies in terms of independent
risk of subsequent resistance (OR, 0.70; 95% CI, 0.20–2.53;
). Finally, severe sepsis or shock as the primary man-Pp .59
ifestation of bacteremia was marginally associated with an in-
creased risk of resistance after controlling for previous antibiotic
therapy.
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Table 3. Multivariate association, averaged across antipseu-
domonal agents, of previous exposure to an agent, and resistance
to that same agent in 267 bacteremic strains of Pseudomonas
aeruginosa.
Characteristic
Adjusted OR
(95% CI) P
Previous monotherapy with
the agent 2.5 (1.3–4.8) .006
Previous combination therapy
including the agent 1.8 (0.55–5.6) .34
Severe sepsis or septic shock 1.6 (0.94–2.6) .08
NOTE. Stratified logistic regression analysis in which each episode of
bacteremia contributed 5 times to the model (i.e., once per antipseudomonal
agent). Variance estimates were adjusted for the resulting dependence among
observations.
DISCUSSION
For clinicians who initiate empiric treatment in a clinical sit-
uation compatible with P. aeruginosa bacteremia, it is crucial
to assess the potential risk of a resistant causative bacterium.
In this retrospective study, 80 (30%) of 267 consecutive bac-
teremic isolates of P. aeruginosa were resistant to 1 antipseu-
domonal drug. Twenty-four percent of bacteremic episodes oc-
curred in patients who had been previously exposed to one or
several of these agents. Imipenem and aminoglycosides were
the most commonly administered antibiotics before the bac-
teremic event, and they were also the agents toward which the
bacteremic isolates were the most frequently resistant. In uni-
variate analysis, previous exposure to ceftazidime, piperacillin,
and imipenem were significantly or marginally associated with
an increased risk of resistance of the bacteremic isolate to them-
selves. After controlling for covariates, the average resistance
of the bacteremic strain to an antibiotic was 2.5 times more
likely when the patient had received previous monotherapy with
this antibiotic that when he had not been exposed to it. No
other treatment variable and none of the characteristics related
to patients and hospital environment independently predicted
resistance of the bacteremic isolate to an antipseudomonal
drug.
Exposure to antibiotics predisposes patients to colonization
with P. aeruginosa intrinsically resistant to these agents. P. aeru-
ginosa has also the capacity to rapidly become resistant during
the course of an antipseudomonal drug treatment [10]. There-
fore, previous therapies increase the risk of infections with se-
lected resistant P. aeruginosa isolates [7]. Moreover, through
the selection of resistant strains, previous exposure to antibi-
otics also increases the risk for the subsequent administration
of an inadequate antimicrobial treatment [11]. Finally, inade-
quate antibiotic treatments of P. aeruginosa bloodstream infec-
tions significantly increase the case-fatality rate [7, 11–13], pro-
long the hospital stay, and generate higher general costs [3, 14].
In this study, aminoglycosides were frequently administered
before the bacteremic event, and resistance toward these agents
was common among the bacteremic isolates. Nevertheless, pre-
vious exposure to aminoglycosides was not associated with an
increased risk of resistance. A possible explanation for this find-
ing is that resistance toward aminoglycosides in these patients
might not be due to a mechanism involving exposure to this
antimicrobial class, but rather to the induction of the MexXY-
OprM efflux system [15] by the exposure to other drugs. This
multidrug efflux system of P. aeruginosa is responsible for re-
sistance to aminoglycosides and is not only induced by exposure
to aminoglycosides, but also by exposure to other classes of
antibiotics such as macrolides or tetracycline [16].
The antibiotic ranking for postexposure risk of resistance dif-
fered in this study and that of Carmeli et al. [10]. In the latter
work, exposure to imipenem was associated with the highest risk
of resistance and ceftazidime with the lowest—findings the op-
posite of ours. Different study populations could explain these
differences. Indeed, the study of Carmeli et al. [10] focused not
only on bacteremic strains, but on both colonizing and invasive
isolates from various clinical sites. In addition, patients included
in the study by Carmeli et al. [10] were initially colonized with
organisms susceptible to the antibiotics to which subsequent
resistance was detected, and a minority of these resistant strains
were proven to have emerged from the original susceptible
clone. However, the study by Carmeli et al. [10] relied upon
an even smaller number of resistant isolates than ours (28 vs.
81). One limitation of our work is the absence of genotyping
of susceptible colonizing and resistant bacteremic strains, mak-
ing it impossible to distinguish new acquisition of resistance
by a previously susceptible strain from superinfection with a
genetically unrelated resistant strain.
Considerable debate exists concerning the usefulness of com-
bination therapies (usually the addition of an aminoglycosides
to a b-lactam antibiotic) in order to reduce the risk of emer-
gence of resistance in P. aeruginosa isolates [17–20]. In contrast
to previous monotherapies, previous combination therapies did
not predict subsequent resistance in this study. However neither
us nor Carmeli et al. [10] found a significant difference in risk
of resistance when monotherapy and combination therapies
were directly compared with each other. We studied one of the
largest retrospective series of P. aeruginosa bacteremia and had
almost no missing information. Nevertheless, our study lacked
power to identify differences in risk of resistance across anti-
biotics, as well as between monotherapy and combination
therapies.
In conclusion, bacteremic events that followed exposure to
antipseudomonal antibiotics were more likely to be due to re-
sistant P. aeruginosa strains. Therefore, when initiating an em-
piric treatment for a possible P. aeruginosa bacteremia, clini-
cians should avoid previously administered antibiotics, and in
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particular, they should avoid those that had been administered
as monotherapies.
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Effectiveness of Combination Antimicrobial Therapy for
Pseudomonas aeruginosa Bacteremia
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It remains controversial whether combination therapy, given empirically or as definitive treatment, for
Pseudomonas aeruginosa bacteremia is associated with a better outcome than monotherapy. The aim of the
present study was to compare the rates of survival among patients who received either combination therapy or
monotherapy for P. aeruginosa bacteremia. We assembled a historical cohort of 115 episodes of P. aeruginosa
bacteremia treated with empirical antipseudomonal therapy between 1988 and 1998. On the basis of suscep-
tibility testing of the bacteremic P. aeruginosa isolate, we defined categories of empirical treatment, including
adequate combination therapy, adequate monotherapy, and inadequate therapy, as well as corresponding
categories of definitive therapy. Neither the adequacy of the empirical treatment nor the use of combination
therapy predicted survival until receipt of the antibiogram. However, the risk of death from the date of receipt
of the antibiogram to day 30 was higher for both adequate empirical monotherapy (adjusted hazard ratio
[aHR], 3.7; 95% confidence interval [CI], 1.0 to 14.1) and inadequate empirical therapy (aHR, 5.0; 95% CI, 1.2
to 20.4) than for adequate empirical combination therapy. Compared to adequate definitive combination
therapy, the risk of death at 30 days was also higher with inadequate definitive therapy (aHR, 2.6; 95% CI, 1.1
to 6.7) but not with adequate definitive monotherapy (aHR, 0.70; 95% CI, 0.30 to 1.7). In this retrospective
analysis the use of adequate combination antimicrobial therapy as empirical treatment until receipt of the
antibiogram was associated with a better rate of survival at 30 days than the use of monotherapy. However,
adequate combination antimicrobial therapy given as definitive treatment for P. aeruginosa bacteremia did not
improve the rate of survival compared to that from the provision of adequate definitive monotherapy.
Pseudomonas aeruginosa bacteremia occurs most frequently
in critically ill patients, particularly those who are immunocom-
promised, have cancer, or are mechanically ventilated (14, 15,
32, 38). In these patients, bacteremia is often accompanied by
symptoms of systemic inflammatory response syndrome
(SIRS) (40). Despite recent advances in therapy, P. aeruginosa
bacteremia remains fatal in more than 20% of cases (28). Over
50% of deaths occur within a few days (3, 13, 18). Therefore,
prompt administration of adequate antipseudomonal treat-
ment is essential (3, 24). Paradoxically, it has not been clearly
established whether the adequacy of empirical antimicrobial
therapy initiated for suspected P. aeruginosa bacteremia truly
improves survival (3, 28, 30, 39). Initial treatment decisions are
difficult to make because P. aeruginosa bacteremia is a pre-
sumptive diagnosis at first and little is known about the sus-
ceptibility of the causative agent until receipt of the antibio-
gram. No single antimicrobial regimen adequately covers all
strains of P. aeruginosa (4, 7). Moreover, the value of combi-
nation therapy (a combination of a beta-lactam plus an ami-
noglycoside or one of these agents plus ciprofloxacin) com-
pared to that of monotherapy remains controversial (9, 10, 12,
16, 22, 29, 37, 39).
We report here on analyses of a retrospective cohort of 115
patients who received empirical therapy for P. aeruginosa bac-
teremia. The patients were monitored from day 1 of docu-
mented bacteremia through day 30. The study aims were three-
fold: (i) to determine whether adequate empirical combination
therapy was associated with a lower rate of mortality during
early follow-up (from the day of documented bacteremia to the
day of receipt of the antibiogram), (ii) whether both empirical
and definitive treatments independently predicted survival dur-
ing late follow-up (from the time of receipt of the antibiogram
to day 30 postbacteremia) among patients who were still alive
at the time of receipt of the antibiogram, and (iii) whether
combination antipseudomonal therapy was superior to mono-
therapy.
MATERIALS AND METHODS
Study population. The study was performed at the Geneva University Hospi-
tal, a 1,000-bed urban tertiary-care center in Geneva, Switzerland. The clinical
microbiology laboratory database was searched to identify all patients with a
positive blood culture for P. aeruginosa from 1 November 1988 to 30 November
1998. Hospital charts were reviewed to further identify patients who presented
with symptoms of SIRS at the time of their bacteremia and who had received an
empirical antimicrobial therapy that included at least one antipseudomonal
agent; no hospital chart was missing. Other data were collected from the same
sources. Because of the rather small sample size, multiple entries in the study
were permitted when two independent episodes of P. aeruginosa bacteremia
occurred in the same patient. The criteria used to designate an independent
episode of P. aeruginosa bacteremia included a documented positive culture for
the pathogen, no antecedent of inadequately treated P. aeruginosa bloodstream
infection, and no positive blood culture for at least 30 days after completion of
adequate antimicrobial therapy for a previous episode of P. aeruginosa bactere-
mia.
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ology and Genetics, Medical School of the University of Geneva,
CMU, 9 av. Champel, CH-1211 Geneva 14, Switzerland. Phone: (4122)
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Dependent variables. The time to death from all causes was used as the
primary outcome of interest to avoid potentially arbitrary distinctions between
deaths related and unrelated to bacteremia episodes.
Categories of antimicrobial treatment. Empirical antipseudomonal therapy
was defined as treatment that included at least one antipseudomonal agent and
that was started no later than 24 h after the index positive blood sample for
culture had been drawn. Definitive antipseudomonal therapy was defined as
treatment that included at least one antipseudomonal agent and that was con-
tinued or commenced on the day that the antibiogram results were reported to
the clinicians. Analyses were based on an intention-to-treat approach; switching
or stopping of the antipseudomonal treatment at any other time during the
course of follow-up was not taken into account. We limited our analyses to
treatments received on the days that the first positive blood sample was drawn
and the results of the antibiogram were received because we lacked information
on why antimicrobial therapy was instituted, modified, or stopped at any other
time during the follow-up. The lack of an ability to appropriately control for
factors that motivate treatment change can result in strong residual confounding
by indication (21). Monotherapy consisted of treatment with one of the following
antipseudomonal antimicrobials: piperacillin, ceftazidime, imipenem, cefepime,
or ciprofloxacin. Piperacillin-tazobactam was used infrequently and was grouped
with piperacillin. Combination therapy consisted of the administration of piper-
acillin, ceftazidime, imipenem, or cefepime together with either an aminoglyco-
side (gentamicin or amikacin) or ciprofloxacin or the administration of an ami-
noglycoside together with ciprofloxacin. Antimicrobial therapy was considered
adequate when the index bacteremic P. aeruginosa isolate was susceptible to the
antimicrobial prescribed and the dose and pattern of administration were in
accordance with current medical standards (piperacillin, 3 to 4 g every 4 h [q4h]
to q6 h; ceftazidime, 2 g q8h; imipenem, 0.5 g q6h; cefepime, 2 g q12h; cipro-
floxacin, 0.4 g intravenously q12h or 0.75 g orally q12h; gentamicin, a load of 2
mg/kg of body weight and then 1.7 mg/kg q8h or 5.1 mg/kg q24h). Combination
therapy was considered adequate if the index bacteremic strain was susceptible
to both drugs. The following antipseudomonal therapies were classified as inad-
equate: monotherapy with an agent to which the bacteremic P. aeruginosa strain
was resistant, combination therapy with two agents to which the strain was
resistant, and combination therapy with an aminoglycoside in association with
another antipseudomonal agent to which the strain was resistant. In our institu-
tion gentamicin is not prescribed at doses exceeding 5.1 mg/kg per day. At this
standard dose, gentamicin monotherapy has been associated with poor outcomes
in patients with P. aeruginosa bacteremia (3, 9, 28). For this reason, in accordance
with the findings of other investigators (37), gentamicin is not accepted as
monotherapy for P. aeruginosa bacteremia in our institution, and patients receiv-
ing empirical aminoglycoside monotherapy were therefore excluded from the
analysis. Several studies have suggested that ciprofloxacin monotherapy might be
effective for febrile neutropenic patients and empirical treatment of bacteremia;
however, higher incidences of superinfections caused by gram-positive patho-
gens, as well as poor outcomes in the case of infections caused by resistant
gram-negative pathogens, have limited its use (1, 25, 31, 33). In contrast, to our
knowledge, no negative data concerning ciprofloxacin monotherapy for the treat-
ment of bacteremia caused by susceptible gram-negative isolates are available
(20). Other investigators have accepted ciprofloxacin monotherapy as an ade-
quate alternative for the treatment P. aeruginosa bacteremia (28, 37). For these
reasons we considered ciprofloxacin monotherapy as an adequate treatment
option, as long as the P. aeruginosa isolate was susceptible.
Hence, we distinguished the following categories of treatment: adequate empirical
combination therapy (AECT), adequate empirical monotherapy (AEMT), inade-
quate empirical therapy (IET), adequate definitive combination therapy (ADCT),
adequate definitive monotherapy (ADMT), and inadequate definitive therapy
(IDT).
Covariates. Other potential prognostic factors were assessed, including age,
sex, calendar year of the patient episode (treated as a dichotomic variable [1993
to 1998 versus 1988 to 1992]), clinical mode of presentation, type of bacteremia
(mono- or polymicrobial), hospital unit, underlying medical condition, initial
neutropenia, steroid treatment, and primary site of infection.
Statistical analysis. Patients for whom the date of receipt of the antibiogram
was missing were excluded from analysis. Statistical analyses were done with the
STATA program (version 6.0). Categorical variables were compared by Fisher’s
exact tests. The Kruskal-Wallis test was used to compare the time to receipt of
the antibiogram across treatment groups. All statistical tests were two tailed.
(i) Survival over entire follow-up. We used the Kaplan-Meier product-limit
method to estimate by univariate analysis the risk of death by empirical treat-
ment categories. The reference time for this preliminary analysis was the day of
the index positive blood culture. Patients were monitored until day 30 postbac-
teremia or were censored from analysis (because of either death or transfer to
another hospital). The log-rank test was used to compare the cumulative prob-
ability of death across treatment groups.
(ii) Early follow-up. Early follow-up started on the date of bacteremia and
extended to the end of the last day before receipt of the antibiogram. Contin-
gency tables were used to compare baseline patient characteristics across em-
pirical treatment groups. We calculated Kaplan-Meier estimates of the cumula-
tive risk of death by patient characteristics. The corresponding unadjusted and
multivariate-adjusted hazard ratios of death were estimated by Cox proportional
hazard regression analysis. Treatment variables were always entered and re-
tained in the multivariate models. Covariates were considered for inclusion if
they were associated with survival with a P value of 0.20 by univariate analysis.
To limit overfitting (11), only important confounding factors (i.e., variables
whose inclusion or exclusion changed regression coefficients of treatments vari-
ables by 10%) were retained in the model; no interaction term was examined.
(iii) Late follow-up. Analyses similar to those described above were performed
for late follow-up, which started on the day of receipt of the antibiogram and
extended to the end of day 30 postbacteremia. Analyses were restricted to
patients who were still alive and who were monitored at the time that the
antibiogram was received. Contingency tables assessed the patients’ character-
istics at the time of bacteremia by definitive treatment groups.
Detailed treatment history. To better define relations between survival and
specified categories of therapies, we identified modifications of empirical ther-
apies before receipt of the antibiogram, as well as changes in definitive therapies
occurring after receipt of the antibiogram. In this analysis, discontinuation fol-
lowing treatment completion was not considered a modification of therapy.
Definitions. Underlying diseases were considered if they were present at the
time of bacteremia and were defined clinically, analytically, hematologically, or
histologically by use of standard criteria (17). Sepsis, severe sepsis, and shock
were defined as described previously (40). Neutropenia was defined as a granu-
locyte count of less than 0.50  109/liter (6). Steroid therapy was considered
notable if the patient had been receiving at least 30 mg of prednisone daily for
at least 10 days before the bacteremia. Definitions of the source of bacteremia
were as described elsewhere (2). The day of antibiogram receipt was defined as
the day when the clinical microbiology laboratory notified the clinician that the
antibiogram had been completed. In our internal experience, the delay between
the sending of the report and its physical receipt by the clinicians did not exceed
6 h. Antimicrobial susceptibility was determined by disk diffusion methods ac-
cording to the recommendations of the National Committee for Clinical Labo-
ratory Standards (NCCLS) (36). An isolate was considered susceptible, interme-
diate, or resistant according to the criteria of the NCCLS. The isolates with
intermediate susceptibility were classified as resistant for analysis.
RESULTS
Baseline characteristics. We identified 120 culture-proven
episodes of P. aeruginosa bacteremia treated empirically with
at least one antipseudomonal agent during the study period.
Five (4.2%) episodes were excluded because of a missing date
of receipt of the antibiogram or missing data on empirical
treatment. Analyses were restricted to 115 episodes of P.
aeruginosa bacteremia in 113 patients. Two patients experi-
enced a second episode of bacteremia after completion of an
adequate antipseudomonal therapy and intervals of 30 and 54
days, respectively. Exclusion of these episodes had virtually no
effects on the overall results. For ease of presentation, we use
the terms episode and patient interchangeably.
About half of the 115 patients were aged 65 years or older;
most were men (Table 1). Half of the bacteremia episodes
occurred between 1993 and 1998. A majority of patients were
hospitalized on the medical ward or surgical intensive care
unit; 19% presented with shock and 12% presented with severe
sepsis. Eighty percent of the episodes were monobacterial. The
most commonly identified sources of P. aeruginosa infection
were the respiratory and urinary tracts. About 90% of patients
had an underlying disease; 30% were neutropenic; 10% were
receiving a steroid treatment. At one time or another during
follow-up, 33 patients (28.7%) received imipenem, 22 (19.1%)
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received piperacillin, 22 (19.1%) received ceftazidime, 12
(10.4%) received cefepime, 56 (48.7%) received gentamicin,
16 (13.9%) received amikacin, and 27 (23.5%) received cipro-
floxacin. Resistance to at least one antipseudomonal agent was
documented for 35% of the P. aeruginosa blood isolates.
Entire follow-up. Complete follow-up was achieved for 114
participants (99%). One patient was transferred to another
hospital on the third day of follow-up. Forty-three patients
(37.4%) had received AECT, 55 (47.8%) had received AEMT,
and 17 (14.8%) had received IET. Forty-five patients died
within 30 days of bacteremia (cumulative risk, 39.4%; 95%
confidence interval [CI], 31.1 to 49.0); 33 deaths (73.3%) were
directly attributed to bacteremia. The unadjusted probabilities
of surviving until day 30 were 72.1% (95% CI, 56.1 to 83.1) for
the AECT group, 61.2% (95% CI, 47.0 to 72.7) for the AEMT
group, and 29.4% (95% CI, 10.7 to 51.2) for the IET group
(Fig. 1) (global test, P  0.01).
Early follow-up. The median time from bacteremia to re-
ceipt of the antibiogram was 5 days (90th percentile, 7 days).
The mean times until receipt of the antibiogram were 5.5 days
for the IET group, 5.2 days for the AEMT group, and 5.1 days
for the AECT group (P  0.60). Most patients’ baseline char-
acteristics were similar across empirical treatment groups (Ta-
ble 2). However, patients who had received AECT were sig-
nificantly more likely to have had their bloodstream infection
between 1988 and 1992 (P  0.001). Sixteen patients died
before the antibiogram was received (cumulative risk, 18.5%;
95% CI, 11.5 to 21.1). By univariate analysis there was no
relation between empirical therapies and risk of death before
receipt of the antibiogram (Table 2). By univariate analysis, the
risk of death was significantly lower among patients over 64
years of age and among those whose bacteremia episode oc-
curred after 1992. Higher risks were observed among patients
who were hospitalized in the surgical intensive care unit, who
presented with severe sepsis or shock, and who had bacteremia
of respiratory origin.
By multivariate analysis, the risk of death before receipt of
the antibiogram was also similar for the AEMT group (adjust-
ed hazard ratio [aHR], 0.81; 95% CI, 0.31 to 2.1; P 0.66) and
the IET group (aHR, 1.2; 95% CI, 0.29 to 5.2; P  0.79)
compared to that for the AECT group (Table 3). Being older
was independently associated with a lower risk of death (aHR,
0.22, 95% CI, 0.06 to 0.81; P  0.02); having presented with
severe sepsis (aHR, 31.5; 95% CI, 3.5 to 286; P  0.002) and
shock (aHR, 38.0; 95% CI, 5.4 to 268; P  0.001) was associ-
ated with a higher risk.
Late follow-up. Of the 99 patients still alive and under fol-
low-up at the time that the antibiogram was received, 1 was
excluded from further analysis because of missing information
on the definitive therapy. Of the 98 remaining patients, 46
(46.9%) had received ADCT, 33 (33.7%) had received ADMT,
and 19 (19.4%) had received IDT (Table 4). Definitive treat-
ment groups were similar with regard to most characteristics
FIG. 1. Cumulative risk of death for patients who received ade-
quate empirical combination therapy (bold solid line), adequate em-
pirical monotherapy (narrow solid line), and inadequate empirical
therapy (broken line).
TABLE 1. Baseline characteristics of 115 P. aeruginosa bacteremic
episodes empirically treated with an antipseudomonal
antimicrobial regimena
Variable No. (%)of episodes
Sex (men) .................................................................................... 85 (73.9)
Calendar time (1993 to 1998)................................................... 56 (48.7)
Hospital unit
Medical .................................................................................... 55 (47.8)
Surgical .................................................................................... 20 (17.4)
Medical intensive care ........................................................... 16 (13.9)
Surgical intensive care ........................................................... 24 (20.9)
Clinical presentation
Simple sepsis ........................................................................... 79 (68.7)
Severe sepsis ........................................................................... 14 (12.2)
Septic shock ............................................................................ 22 (19.1)
Monobacterial bacteremia ........................................................ 92 (80.0)
Primary site(s) of P. aeruginosa infection
Respiratory tract..................................................................... 24 (20.9)
Urinary tract ........................................................................... 22 (19.1)
Vascular system ...................................................................... 5 (4.3)
Other........................................................................................ 21 (18.3)
Unknown ................................................................................. 57 (49.6)
Underlying medical condition
Cancer...................................................................................... 52 (15.2)
AIDS........................................................................................ 6 (5.2)
Diabetes................................................................................... 9 (7.8)
Respiratory dysfunction......................................................... 23 (20.0)
Renal failure ........................................................................... 19 (16.5)
Otherb ...................................................................................... 50 (43.5)
None of the above.................................................................. 15 (13.0)
Neutropenia ............................................................................ 34 (29.6)
Steroid treatment ................................................................... 11 (9.6)
Bacteremic strain resistant to the following no. of
antipseudomonal agents:
0 ................................................................................................ 75 (65.2)
1 ................................................................................................ 19 (16.5)
2............................................................................................. 21 (18.3)
a The median age was 65 years (age range, 6 to 91 years).
b Heart failure, pancreatitis, and severe nonpseudomonal infection.
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recorded at the time of bacteremia. However, definitive anti-
microbial therapy of a particular type (i.e., adequate combina-
tion therapy, adequate monotherapy, or inadequate therapy)
was significantly more likely to have followed an empirical
treatment of the same type (P  0.001). Twenty-nine patients
died before the end of follow-up (cumulative risk, 32.4%; 95%
CI, 23.3 to 43.9).
In contrast to the risk of death during early follow-up, the
risk of death after receipt of the antibiogram varied according
to empirical therapy. By univariate analysis, the risk of death
was significantly higher for the IET group (crude hazard ratio
[cHR], 6.8; 95% CI, 2.3 to 20.3) and marginally higher for the
AEMT group (cHR, 2.5, 95% CI, 0.88 to 6.9) than for the
AECT group (Table 4). The multivariate Cox proportional
hazard model was stratified on severe sepsis and shock to limit
violation of the proportional hazard assumption. After further
controlling for independent prognostic factors and definitive
treatment, patients in the AEMT group were 3.7 times more
TABLE 2. Baseline characteristics of study subjects in relation to categories of empirical antimicrobial therapy and summary of univariate
survival analysis until receipt of the antibiograma
Characteristic
% of episodes with:
No. who died/total no.
(Kaplan-Meier %)b
Univariate HR
(95% CI) P value
Adequate
combination
therapy
(n  43)
Adequate
monotherapy
(n  55)
Inadequate
therapy
(n  17)
All patients 100.0 100.0 100.0 16/115 (18.5)
Empirical antimicrobial therapy
Adequate combination therapy 100.0 0.0 0.0 7/43 (29.7) 1.0 (referent)
Adequate monotherapy 0.0 100.0 0.0 6/55 (11.1) 0.67 (0.23–1.9) 0.46
Inadequate therapy 0.0 0.0 100.0 3/17 (17.7) 1.1 (0.29–4.5) 0.86
Age (yr)
65 41.2 49.1 51.2 13/56 (34.7) 1.0 (referent)
65 58.8 50.9 48.8 3/59 (5.1) 0.20 (0.06–0.69) 0.01
Calendar time
1988 to 1992 69.8 47.3 17.6 9/39 (36.4) 1.0 (referent)
1993 to 1998 30.2 52.7 82.4 7/76 (9.5) 0.38 (0.14–1.0) 0.05
Hospitalized on surgical intensive
care unit
No 83.7 80.0 64.7 9/91 (13.2) 1.0 (referent)
Yes 16.3 20.0 35.3 7/24 (35.7) 3.2 (1.2–8.5) 0.02
Clinical presentation
Simple sepsis 67.4 69.1 70.6 1/79 (1.3) 1.0 (referent)
Severe sepsis 18.6 10.9 0.0 7/14 (42.9) 28.1 (3.4–229.9) 0.002
Shock 14.0 20.0 29.4 10/22 (56.3) 45.5 (5.9–348.3) 0.001
Type of bacteremia
Pseudomonas alone 74.4 85.5 76.5 12/92 (20.9) 1.0 (referent)
Poymicrobial 25.6 14.5 23.5 4/23 (17.4) 0.88 (0.27–2.8) 0.83
Underlying medical condition(s)c
No 14.0 14.5 5.9 2/15 (13.3) 1.0 (referent)
Yes 86.0 85.5 94.1 14/100 (19.6) 1.8 (0.22–14.6) 0.58
Immunological risk factor(s)
None of the following 55.8 67.3 70.6 7/73 (12.2) 1.0 (referent)
Neutropenia 39.5 25.5 17.6 6/34 (18.3) 2.0 (0.68–5.8) 0.21
Steroid treatment 7.0 10.9 11.8 3/11 (59.1) 3.4 (0.95–12.0) 0.06
Neutropenia and/or steroid
treatment
44.2 32.7 29.4 9/42 (33.4) 2.6 (0.96–7.0) 0.06
Primary site(s) of infection
Unknown 51.2 52.7 35.3 7/57 (13.0) 1.0 (referent)
Respiratory tract 20.9 16.4 35.3 8/24 (55.0) 2.9 (1.1–7.5) 0.03
Urinary tract 20.9 20.0 11.8 0/22 (0.0) 0.0 (NDd) ND
Vascular system 4.7 5.5 0.0 0/5 (0.0) 0.0 (ND) ND
Other 20.9 14.5 23.5 3/21 (14.3) 1.2 (0.30–4.4) 0.83
a Seven episodes of bacteremia were excluded from this analysis either because of missing empirical treatment (n  2) or missing dates of receipt of the antibiogram
(n  5).
b Kaplan-Meier product limit estimate of cumulative risk of death from all causes.
c Cancer, AIDS, diabetes, respiratory dysfunction, renal failure, heart failure, pancreatitis, and/or severe nonpseudomonal infection.
d ND, not defined.
VOL. 47, 2003 COMBINATION THERAPY AND P. AERUGINOSA BACTEREMIA 2759
likely (95% CI, 1.0 to 14.1; P  0.05) and patients in the IET
group were 5.0 times more likely (95% CI, 1.2 to 20.4; P 
0.02) to have died during late follow-up than patients in the
AECT group (Table 5). There was no independent difference
in the risk of death between patients in the IET and AEMT
groups (aHR, 1.3; 95% CI, 0.54 to 3.3; P  0.52).
Adequate definitive therapies were associated with better
outcomes, but there was no evidence for the superiority of
combination therapy over monotherapy. By univariate analysis,
the risk of death for the ADMT group (cHR, 1.2; 95% CI, 0.50
to 2.9) was similar to that for the ADCT group, but the risk of
death was significantly higher for the IDT group (cHR, 3.6,
95% CI, 1.4 to 8.9) than for the ADCT group (Table 4).
Hospitalization on the surgical intensive care unit and severe
sepsis or shock at the time of bacteremia were significant
predictors of poor survival. There was a trend for bacteremia
of urinary and vascular origin to be associated with a better
prognosis. By multivariate analysis, the risk of death was sig-
nificantly higher for the IDT group (aHR, 2.6; 95% CI, 1.1 to
6.7; P  0.04) but not for the ADMT group (aHR, 0.70; 95%
CI, 0.30 to 1.7; P  0.42) compared to that for the ADCT
group (Table 5). Hospitalization on the surgical intensive care
unit was independently associated with poor survival (aHR,
3.2; 95% CI, 1.2 to 8.9; P 0.02), and bacteremia of urinary or
vascular origin was associated with better survival (aHR, 0.21;
95 CI, 0.05 to 0.94; P  0.04).
Details on treatment changes during follow-up. Empirical
treatment was unmodified until receipt of the antibiogram (or
death for those who died during early follow-up) in 80 of 115
patients (Table 6). A switch of therapy during early follow-up
was recorded for 18.6% of patients in the AECT group, 38.2%
of those in the AEMT group (relative risk [RR], 2.1; 95% CI,
1.0 to 4.2; P 0.05), and 35.3% of those in the IET group (RR,
1.9; 95% CI, 0.77 to 4.7; P  0.19) (Table 6). No adequate
empirical combination therapy was modified on the day of
receipt of the antibiogram, while three AEMTs (8.8%) were
replaced by an ADCT and one IET (4.8%) was replaced by an
ADMT. Finally, 13 definitive treatments were modified before
the end of follow-up or death: 5 of these changes (38.5%)
consisted of downgrading of an ADCT to an ADMT, while 3
(23.0%) consisted of upgrading of an ADMT to an ADCT, and
5 (38.5%) consisted of upgrading of an IDT to either an
ADMT or an ADCT.
Monotherapy subanalysis. The adequacies of both amino-
glycoside monotherapy and ciprofloxacin monotherapy for
P. aeruginosa bacteremia are controversial. Therefore, we
conducted complementary univariate analyses to describe
the risk of death among patients treated with aminoglyco-
side or ciprofloxacin monotherapy and examined the impact
of alternative definitions of monotherapy adequacy on the
results of multivariate analysis. The crude cumulative risk of
death during follow-up was 35.0% (95% CI, 18.5 to 59.7%)
for 20 patients who received an active aminoglycoside
monotherapy empirically. The crude cumulative risks of
death were 25% (95% CI, 11.3 to 50.0%) before receipt of
the antibiogram and 15.2% (95% CI, 4.0 to 48.8%) after
receipt of the antibiogram. Among 12 patients who received
active ciprofloxacin monotherapy empirically, the crude cu-
mulative risks of death were 33.3% (95% CI, 14.0 to 66.3%)
over the entire follow-up, 0% before receipt of the antibio-
gram, and 34.4% (95% CI, 14.4 to 68.0%) after receipt of
the antibiogram. The crude risk of death before receipt of
the antibiogram was marginally higher among patients who
received empirical aminoglycoside monotherapy than
among patients who received empirical ciprofloxacin mono-
therapy (P  0.07; HR was undefined). There was a trend in
the opposite direction for the risk of death after receipt of
the antibiogram (cHR, 0.21; 95% CI, 0.11 to 1.9; P  0.16).
In our main analysis sections, to reflect the consensus that
has been achieved in our institution, we excluded patients
who received empirical combination therapy with an active
aminoglycoside associated with a nonantipseudomonal
agent and included in the inadequate therapy groups pa-
tients who received an active aminoglycoside in combination
with an inactive antipseudomonal agent. In contrast, we
included in the adequate monotherapy groups patients who
received active ciprofloxacin in combination with either a
nonantipseudomonal agent or an inactive antipseudomonal
agent. As a complement, we conducted two additional mul-
tivariate analyses. In the first one, monotherapy with an
active aminoglycoside and monotherapy with active cipro-
floxacin were both considered adequate; in the second one,
neither regimen was considered adequate. Both analyses
confirmed that inadequate empirical and definitive thera-
pies were associated with poor outcomes; both analyses also
supported the notion that the type of empirical therapy is
not an independent predictor of death before receipt of the
antibiogram (data not shown). Moreover, the aHRs at 30
days for patients in the AEMT group compared to that for
patients in the AECT group were 2.0 in the first analysis
(95% CI, 0.67 to 6.2) and 2.3 in the second analysis (95% CI,
0.62 to 8.7). Although neither result was statistically signif-
icant, both concur with the findings of the main multivariate
analyses in suggesting that adequate empirical combination
therapy was associated with better outcomes at day 30 than
adequate empirical monotherapy.
TABLE 3. Results of a Cox proportional hazard model describing
independent relations between empirical antimicrobial therapy and
risk of death during early follow-upa
Characteristic Hazardratio 95% CI P value
Empirical antimicrobial therapy
Adequate combination therapy 1.0
Adequate monotherapy 0.81 0.31–2.1 0.66
Inadequate therapy 1.2 0.29–5.2 0.79
Age (yr)
65 1.0
65 0.22 0.06–0.81 0.02
Clinical presentation
Simple sepsis 1.0
Severe sepsis 31.5 3.5–286.4 0.002
Shock 38.0 5.4–267.8 0.001
a Early follow-up started on the date of bacteremia and extended to the end of
the last day before receipt of the antibiogram. Similar results were obtained after
exclusion of the 26 patients who had a known urinary or vascular source of P.
aeruginosa infection.
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TABLE 4. Baseline characteristics of study subjects in relation to categories of definitive antipseudomonal therapy and summary of univariate
survival analysis from receipt of the antibiogram to end of follow-up for 98 patientsa
Characteristic
% of episodes with:
No. who died/total no.
(Kaplan-Meier %)b
Univariate HR
(95% CI) P value
Adequate
combination
therapy
(n  46)
Adequate
monotherapy
(n  33)
Inadequate
therapy
(n  19)
All patients 100.0 100.0 100.0 29/98 (32.4)
Empirical antimicrobial therapy
Adequate combination therapy 58.7 12.1 26.3 5/36 (16.0) 1.0 (referent)
Adequate monotherapy 30.4 81.8 42.1 15/49 (33.9) 2.5 (0.88–6.9) 0.09
Inadequate therapy 10.9 6.1 31.6 9/13 (71.2) 6.8 (2.3–20.3) 0.001
Adequate monotherapy or
inadequate therapy
41.3 87.9 73.7 24/62 (42.1) 3.2 (1.2–8.4) 0.02
Definitive antimicrobial therapy
Adequate combination therapy 100.0 0.0 0.0 10/46 (21.7) 1.0 (referent)
Adequate monotherapy 0.0 100.0 0.0 9/33 (32.5) 1.2 (0.50–2.9) 0.68
Inadequate therapy 0.0 0.0 100.0 10/19 (57.9) 3.6 (1.4–8.9) 0.006
Adequate monotherapy or
inadequate therapy
0.0 100.0 100.0 19/52 (42.2) 1.8 (0.86–4.0) 0.12
Age (yr)
65 47.8 39.4 42.1 11/43 (28.8) 1.0 (referent)
65 52.2 60.6 57.9 18/55 (35.4) 1.3 (0.60–2.7) 0.54
Calendar time
1988 to 1992 50.0 45.5 36.8 8/30 (31.1) 1.0 (referent)
1993 to 1998 50.0 54.5 63.2 21/68 (33.1) 1.1 (0.51–2.6) 0.74
Hospitalized on surgical intensive
care unit
No 78.3 84.8 89.5 20/81 (28.0) 1.0 (referent)
Yes 21.7 15.2 10.5 9/17 (52.9) 2.9 (1.3–6.6) 0.009
Clinical presentation
Simple sepsis 76.1 78.8 84.2 17/77 (24.1) 1.0 (referent)
Severe sepsis 8.7 9.1 10.5 4/8 (100.0) 2.6 (1.0–6.7) 0.05
Shock 15.2 12.1 5.3 8/13 (61.5) 4.1 (1.7–9.8) 0.002
Type of bacteremia
Pseudomonas alone 78.3 87.9 78.9 24/80 (32.3) 1.0 (referent)
Poymicrobial 21.7 12.1 21.1 5/18 (30.2) 1.0 (0.42–2.6) 0.95
Underlying medical condition(s)c
No 10.9 21.2 5.3 2/13 (16.1) 1.0 (referent)
Yes 89.1 78.8 94.7 27/85 (34.8) 2.3 (0.56–9.1) 0.25
Immunological risk factor(s)
None of the following 60.5 81.3 72.2 18/65 (30.4) 1.0 (referent)
Neutropenia 39.5 18.8 27.8 8/28 (31.8) 1.1 (0.47–2.5) 0.87
Steroid treatment 13.3 7.1 13.3 4/8 (50.0) 2.0 (0.69–5.8) 0.20
Primary site(s) of infection
Unknown 47.8 45.5 68.4 15/50 (33.4) 1.0 (referent)
Respiratory tract 17.4 15.2 15.8 7/16 (44.4) 1.5 (0.63–3.6) 0.35
Urinary tract 17.4 33.3 10.5 3.21 (19.6) 0.39 (0.12–1.2) 0.11
Vascular system 8.7 3.0 0.0 0/5 (0.0) 0.0 (NDd) ND
Other 26.1 9.1 15.8 6/18 (33.3) 1.1 (0.41–2.8) 0.89
Time between bacteremia and
receipt of antibiogram
(days)
5 52.2 51.5 31.6 16/47 (34.0) 1.0 (referent)
5 47.8 48.5 68.4 13/51 (25.7) 0.89 (0.42–1.9) 0.75
a One additional patient was excluded from this analysis because of missing definitive treatment.
b Kaplan-Meier product limit estimate of cumulative risk of death from all causes.
c Cancer, AIDS, diabetes, respiratory dysfunction, renal failure, heart failure, pancreatitis, and/or severe nonpseudomonal infection.
d ND, not defined.
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DISCUSSION
In our cohort of patients with P. aeruginosa bacteremia and
SIRS, adequate empirical combination therapy was indepen-
dently associated with better survival at 1 month compared to
that achieved with adequate empirical monotherapy. In con-
trast, the rates of mortality prior to receipt of the antibiogram
were similar among those who had received no, one, or two
adequate antipseudomonal agents. Adequate definitive mono-
therapy and adequate definitive combination therapy were
both independently associated with better survival outcome
compared to survival achieved with inadequate definitive ther-
apy.
Both the importance of an appropriate empirical therapy
and the role of combination therapies for P. aeruginosa bacte-
remia are controversial. Unfortunately, cases of P. aeruginosa
bacteremia have only rarely been included in randomized
treatment trials. Indeed, in a review of 10 randomized trials of
antimicrobial therapy in patients with cancer and neutropenia,
only 90 of a total of 909 episodes of bacteremia were caused by
Pseudomonas species, and there was no subgroup analysis of
treatment efficacy by organism (16). Therefore, present guide-
lines rely mostly on observational studies. Inappropriate defin-
itive therapy for P. aeruginosa bacteremia was a predictor of
poor clinical outcome in most recently published observational
studies (3, 9, 24, 28, 39), and the importance of the appropri-
ateness of definitive treatment for P. aeruginosa bacteremia is
therefore generally accepted. A delay in the administration of
appropriate antimicrobial therapy has been associated with
lower cure rates in some studies (3, 30); however, this was not
confirmed by others (28, 39). Similarly, combination therapy
was superior to monotherapy in one study (22), but not in
others (3, 9, 28, 37, 39). A major shortcoming of previous
observational studies is the possible bias due to the death of
some patients before they matched the definition for a partic-
ular treatment category (e.g., therapy was received for at least
2 days) (22). Comparison between the available studies is also
made difficult by different study designs. Some were prospec-
tive (22, 39), some excluded polymicrobial bacteremia (9, 28),
some did not use overall survival as the main outcome (3, 9),
and, most importantly, some did not account for the results of
in vitro susceptibility testing in the definition of adequate ther-
apy (3, 9). Moreover, monotherapy with an aminoglycoside,
which nowadays is not accepted as an appropriate therapy for
P. aeruginosa bacteremia unless high doses (7 mg/kg/day) are
used, was considered appropriate in previous studies (3, 9, 28).
In other studies, this issue was not addressed (22, 39), and it is
therefore possible that the superiority of combination therapy
over monotherapy resulted from the inclusion in the mono-
therapy group of patients who had been treated with standard
doses of an aminoglycoside alone (22). Present guidelines for
the treatment of suspected P. aeruginosa bacteremia recom-
mend the rapid introduction of empirical antimicrobial therapy
that includes at least one antipseudomonal agent. Some inves-
tigators, because of worry regarding initial resistance to the
empirically chosen antipseudomonal agent, suggest the addi-
tion of an aminoglycoside for 3 to 5 days (10, 12). This is
indeed a serious concern, as the prevalence of resistance of the
invasive strain to antipseudomonal agents was higher in our
cohort than in older series (3, 22, 28). Empirical combination
therapy could also reduce the risk of selection of resistant
clones during initial therapy (5, 7, 26, 34, 35). This is supported
by our recent findings suggesting differences in the susceptibil-
ity patterns of bacteremia-causing P. aeruginosa isolates previ-
ously exposed to monotherapies and combination therapies
(4). The emergence of antimicrobial resistance during therapy
for P. aeruginosa bacteremia is difficult to detect and may lead
to inappropriate definitive therapy, with increased rates of
mortality and prolonged hospital stays (8, 24, 27). Moreover,
greater killing might be achieved by combination therapies
acting synergistically; this might be of particular importance
early during the infectious process, when a rapid reduction of
the pathogen burden might prevent the evolution toward sep-
sis. One concern with combination therapies is the risk of
nephrotoxicity or ototoxicity when aminoglycosides are used
(12). It is therefore recommended that aminoglycosides be
given only for a short time (3 to 5 days) (10, 12). This approach
is supported by the present study, which suggests that empirical
combination therapy increases survival at 30 days, even if it is
given for only 3 to 5 days and is followed by monotherapy.
Why does empirical therapy not influence mortality until
receipt of the antibiogram? One reasonable hypothesis is that
some patients are so sick that they will die within the first days
following P. aeruginosa bacteremia, independently of any an-
timicrobial therapy. In contrast, patients in better clinical con-
dition at the time of P. aeruginosa bacteremia might survive a
few days independently of the appropriateness of antimicrobial
treatment. Evidence supporting this hypothesis comes from
the observation that clinical presentation at the onset of bac-
teremia is the strongest independent indicator of survival.
Like others (39), we observed that inadequate empirical
antimicrobial therapies had sometimes not been modified ac-
cording to the antibiogram results. It is likely that favorable
TABLE 5. Results of a stratified Cox proportional hazard model
describing independent relations between both empirical and
definitive antimicrobial therapy and risk of death during
late follow-upa
Characteristic Hazardratio 95% CI P value
Empirical antimicrobial therapy
Adequate combination therapy 1.0
Adequate monotherapy 3.7 1.0–14.1 0.05
Inadequate therapy 5.0 1.2–20.4 0.02
Definitive antimicrobial therapy
Adequate combination therapy 1.0
Adequate monotherapy 0.70 0.30–1.7 0.42
Inadequate therapy 2.6 1.1–6.7 0.04
Hospitalization on the surgical
intensive care unit
No 1.0
Yes 3.2 1.2–8.9 0.02
Bacteremia of urinary or vascular
origin
No 1.0
Yes 0.21 0.05–0.94 0.04
a The model was stratified on dummy variables coding for severe sepsis and
shock to account for violations of the proportional hazard assumption. Late
follow-up started on the day of receipt of the antibiogram and extended to the
end of day 30 post bacteremia.
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evolution, despite treatment inadequacy, influenced the clini-
cian’s decisions in this sense. Older age was unexpectedly as-
sociated with better survival. However, our restrictive inclusion
criteria (positive blood culture for P. aeruginosa in association
with SIRS and administration of an empirical antimicrobial
therapy that included at least one agent with antipseudomonal
activity) probably selectively excluded from analysis elderly
patients with poor prognoses. Indeed, blood samples for cul-
ture were probably less frequently obtained from elderly pa-
tients who had underlying conditions associated with a very
poor prognosis. The elderly patients included in the analysis
were also significantly more likely than younger patients to
have characteristics associated with a better outcome (bacte-
remia of urinary origin, no neutropenia, and no steroid treat-
ment).
Our study design was based on recommendations for high-
quality observational studies for the evaluation of therapeutic
effectiveness (19, 23). Nevertheless, we cannot exclude the
possibility that estimates of treatment effects were biased by an
imbalance associated with the therapeutic choices not ac-
counted for in the multivariate analyses. This seems unlikely,
because clinicians were uncertain about the diagnosis of P.
aeruginosa bacteremia and unaware of the susceptibility to
antimicrobials of the infecting strain at the time that they
initiated empirical antimicrobial therapy. Because our sample
size was small from a statistical viewpoint, multivariate analy-
ses assessed only a limited number of therapy categories and
controlled for only a few covariates simultaneously. Finally,
analysis could not account for intercurrent treatment modifi-
cations which should have led to an attenuation of the ob-
served differences in mortality across treatment groups.
We suggest that clinicians who suspect P. aeruginosa bacte-
remia initiate empirical therapy with two antipseudomonal
agents. In the case of proven P. aeruginosa bacteremia, this
combination therapy could be changed to monotherapy on the
basis of the specific susceptibility pattern of the initial isolate.
It is hoped that such an approach may reduce the risk of
TABLE 6. Modifications of antimicrobial therapy within 30 days postbacteremia
Treatment type, time of modification Modification No. (%) of episodes
Empirical antimicrobial therapy, during early follow-up
Adequate combination therapy (n  43) No modification 35 (81.4)
Switch to adequate monotherapy 6 (14.0)
Switch to inadequate therapy 2 (4.6)
Adequate monotherapy (n  55) No modification 34 (61.8)
Switch to adequate combination therapy 12 (21.8)
Switch to inadequate therapy 9 (16.4)
Inadequate therapy (n  17) No modification 11 (64.7)
Switch to adequate combination therapy 5 (29.4)
Switch to adequate monotherapy 1 (5.9)
Empirical antimicrobial therapy, at receipt of antibiograma
Adequate combination therapy (n  43) No modification 43 (100.0)
Switch to adequate monotherapy 0 (0.0)
Switch to inadequate therapy 0 (0.0)
Adequate monotherapy (n  34) No modification 31 (91.2)
Switch to adequate combination therapy 3 (8.8)
Switch to inadequate therapy 0 (0.0)
Inadequate therapy (n  21) No modification 20 (95.2)
Switch to adequate combination therapy 0 (0.0)
Switch to adequate monotherapy 1 (4.8)
Definitive antimicrobial therapy, during late follow-upb
Adequate combination therapy (n  46) No modification 39 (92.0)
Switch to adequate monotherapy 5 (8.0)
Switch to inadequate therapy 0 (0.0)
Adequate monotherapy (n  33) No modification 30 (83.6)
Switch to adequate combination therapy 3 (16.4)
Switch to inadequate therapy 0 (0.0)
Inadequate therapy (n  19) No modification 11 (70.1)
Switch to adequate combination therapy 1 (9.0)
Switch to adequate monotherapy 4 (20.9)
a Sixteen patients died before receipt of the antibiogram; data on treatment modification between day 2 and the last day before receipt of the antibiogram were
missing for one patient.
b Four patients died on the day of receipt of the antibiogram; data on treatment modifications after receipt of the antibiogram were missing for one patient.
VOL. 47, 2003 COMBINATION THERAPY AND P. AERUGINOSA BACTEREMIA 2763
selection of antimicrobial agent-resistant strains and avoid in-
adequate empirical therapies without increasing the risk of
drug toxicity.
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CONCLUSION 
 
 
 
P. aeruginosa is an increasingly prevalent opportunistic human pathogen, which is of special 
interest to the hospital physician. Amongst the numerous attributable infections it can produce, 
bacteremia is especially feared because of the high mortality and the difficulty to choose the 
appropriate antibiotic therapy. 
This work was designed to study three important and controversial issues of P. aeruginosa 
bacteremia: (I) does preceding exposure to antibiotics increase the risk of resistance of the bacteremic 
strain ? (II) what is the influence of empirical and definitive treatment on survival ? and (III) does the 
use of a combination therapy as empirical and/or definite therapy improve the outcome ? 
To address these questions we studied retrospectively all the P. aeruginosa bacteremias that 
occurred during a ten year period at the University Hospital of Geneva. 
In the first article related to the influence of preceding antibiotic therapy on the susceptibility pattern of 
P. aeruginosa bacteremic isolates, the univariate analysis revealed that previous exposure to 
ceftazidime, piperacillin and imipenem were associated with an increased risk of resistance of the 
bacteremic isolates to themselves. The multivariate analysis showed a 2,5 time increase in the risk of 
resistance among the isolates of episodes of bacteremia which had been preceded by the exposure to an 
antibiotic as a monotherapy.  
In the second article we analyzed the impact of combination versus monotherapy during both 
empirical and definite therapy for P. aeruginosa bacteremia on survival at the time the resistance 
profile of the bacteremic strain became available and at one month. We were unable to detect a relation 
between adequacy of the empirical therapy and the risk of death before reception of the antibiogram, 
mortality being influenced at that stage by age and clinical presentation. On the contrary, late outcome 
varied according to empirical and definitive therapy. Better survival at one month was independently 
associated with an adequate empirical combination therapy and with either an adequate definitive 
mono or combination antibiotherapy. 
Together these findings led us to conclude that, when initiating an empiric treatment for a 
possible P. aeruginosa bacteremia, clinicians should avoid previously administered antibiotics 
especially if these have been given as monotherapy. We recommend the rapid introduction of a 
combination therapy while awaiting the result of the antibiogram. This combination therapy can be 
40
safely switched to an adequate monotherapy based on the resistance profile of the bacteremic strain 
after 3 to 5 days 
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RESUME EN FRANCAIS 
 
 
 
Pseudomonas aeruginosa représente la 3 ème cause de bactériémie à Gram-négatif et est 
associé à une mortalité de 25%. 
Nous avons étudié la relation entre l’exposition préalable à certains antibiotiques 
antipseudomonaux et les résistances des souches bactériémiques. Le risque de résistance à la 
ceftazidime, à l’imipenem et à la pipéracilline augmente significativement. Les souches, dont 
l’épisode de bactériémie a été précédé par l’exposition à un antibiotique sous forme de 
monothérapie ont 2,5 fois plus de risque d’être résistantes à cet agent, comparé à son exposition en 
bithérapie. 
Une bithérapie empirique adéquate, ainsi qu’une mono et bithérapie définitive adéquate sont 
associées à une meilleure survie des patients à un mois. 
Lors de bactériémie à P. aeruginosa, nous recommandons d’introduire une bithérapie en 
évitant tout antibiotique ayant été employé avant l’épisode de bactériémie. Cette bithérapie pourra 
être remplacée ultérieurement par une monothérapie adéquate, basée sur l’antibiogramme de la 
souche bactériémique. 
